

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

# **BMJ Open**

### Sarcopenia in Systemic Sclerosis: Prevalence and Impact - A Systematic Review and Meta-analysis

Journal:	BMJ Open							
Manuscript ID	bmjopen-2023-078034							
Article Type:	Original research							
Date Submitted by the Author:	22-Jul-2023							
Complete List of Authors:	Tu, Xiangping; Sichuan University West China Hospital, Department of Geriatrics; Sichuan University West China Hospital, National Clinical Research Center for Geriatrics Lin, Taiping; Sichuan University West China Hospital, Department of Geriatrics; Sichuan University West China Hospital, National Clinical Research Center for Geriatrics Ju, Yuan; Sichuan University, Sichuan University library Shu, Xiaoyu; Sichuan University West China Hospital, Department of Geriatrics; Sichuan University West China Hospital, National Clinical Research Center for Geriatrics Jiang, Tingting; Sichuan University West China Hospital, Department of Geriatrics; Sichuan University West China Hospital, National Clinical Research Center for Geriatrics Ge, Ning; Sichuan University West China Hospital, Department of Geriatrics; Sichuan University West China Hospital, National Clinical Research Center for Geriatrics Yue, Jirong; Sichuan University West China Hospital, Department of Geriatrics; Sichuan University West China Hospital, National Clinical Research Center for Geriatrics							
Keywords:	Rheumatology < INTERNAL MEDICINE, GERIATRIC MEDICINE, Systematic Review							

SCHOLARONE™ Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

_	
1 2 3	
4 5	1
6 7	2
8 9 10	3
11 12	4
13 14 15	5
16 17 18	6
19 20	7
21 22 23	8
24 25	9
26 27 28	10
29 30	11
31 32 33	12
34 35	13
36 37 38	14
39 40	15
41 42 43	16
44 45	17
46 47 48	18
49 50 51	19
52 53	20
54 55 56	21
57 58	
59	22

1	Sarcopenia in Systemic Sclerosis: Prevalence and Impact - A Systematic Review and
2	Meta-analysis
3	Xiangping Tu, <sup>1</sup> Taiping Lin, <sup>1</sup> Yuan Ju, <sup>2</sup> Xiaoyu Shu, <sup>1</sup> Tingting Jiang, <sup>1</sup> Ning Ge, <sup>1</sup> Jirong Yue <sup>1*</sup>
4	<sup>1</sup> Department of Geriatrics and National Clinical Research Center for Geriatrics, West China
5	Hospital, Sichuan University, Chengdu Sichuan, China, <sup>2</sup> Sichuan University Library, Chengdu
6	Sichuan, China.
7	Correspondence to: Dr. Jirong Yue, Department of Geriatrics, West China Hospital, Sichuan
8	University, Chengdu Sichuan, 610041, China, <u>yuejirong11@hotmail.com</u> ; Telephone
9	+8618980601143.
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	

#### 1 Abstract

- **Objective** This review aims to provide an estimate of sarcopenia prevalence and its impact
- 3 on clinical characteristics in patients with systemic sclerosis (SSc).
- **Design** Systematic review and meta-analysis
  - Methods We systemically searched Embase, Medline, Web of Science, and the Cochrane
- 6 Central Register of Controlled Trials from inception to May 24, 2023. Observational studies
- 7 that reported the prevalence of sarcopenia in patients with SSc were included. Clinical
- 8 characteristics from studies that compared SSc patients with and without sarcopenia were
- 9 analyzed and expressed as mean difference (MD) or standardized mean difference (SMD)
- with a 95% confidence interval (CI).
- **Results** A total of 4583 articles were screened and 9 studies with data from 815 patients were
- included in the analysis (8 cross-sectional studies and 1 retrospective cohort study). The
- overall prevalence of sarcopenia in SSc patients was 22% (95% CI 17%-28%). SSc patients
- with sarcopenia had a poorer quality of life (MD -12.02; 95% CI -19.11 to -4.93) and higher
- 15 CRP levels (SMD 0.67; 95% CI 0.35 to 1.00).
- 16 Conclusions Our study conducted a comprehensive analysis and determined a notable
- 17 prevalence of sarcopenia in patients diagnosed with SSc. SSc patients with sarcopenia had a
- worse quality of life and higher CRP levels, based on our findings. Given the detrimental
- impact of sarcopenia on quality of life, future efforts aimed at early identification of sarcopenia
- in the clinical assessment of patients with SSc may have significance.
- **PROSPERO registration number** CRD42022368326
- **Keywords** Sarcopenia; Systemic sclerosis; Meta-analysis; Prevalence

- 2 This is the first systematic review and meta-analysis to evaluate the prevalence and impact of
- 3 sarcopenia in patients with systemic sclerosis.
- 4 We conducted a comprehensive literature search to ensure that all eligible studies were
- 5 included in the analysis.
- 6 We could not establish a definitive causal relationship between sarcopenia and systemic
- 7 sclerosis.
- 8 Even though this review included studies from different continents (European, South America,
- 9 and Asia), data on participant race were not accessible, limiting its potential applicability to
- 10 specific patient subgroups.

### Introduction

Systemic sclerosis (SSc) is a rare immune-mediated rheumatic disease that is characterized by inflammation, microvascular damage, and progressive fibrosis of both the skin and internal organs, such as the gastrointestinal tract, lung, heart, and kidney. 1,2 Depending on the extent of cutaneous involvement, SSc can be classified as limited cutaneous SSc (lcSSc) or diffuse cutaneous SSc (dcSSc).<sup>3</sup> Patients with SSc are at risk for body composition abnormalities, including loss of skeletal muscle mass, due to malnutrition resulting from gastrointestinal involvement, chronic inflammation, and steroid therapy.<sup>4–7</sup> In addition, heart, lung, and joint involvement in SSc patients can lead to impaired exercise ability and decreased physical activity.<sup>8</sup> These factors are closely related to sarcopenia, which is an age-related disease characterized by progressive and generalized loss of skeletal muscle mass and strength.<sup>9</sup> The coexistence of sarcopenia and SSc can exacerbate the patient's health issues and increase their healthcare costs, posing significant challenges for healthcare professionals. According to a meta-analysis, the prevalence of sarcopenia in community-dwelling elders aged over 60 years was 11% (95% CI: 8-13%) in men and 9% (95% CI: 7-11%) in women. 10 The presence of sarcopenia increases the risk of falling, functional decline, frailty, and mortality, leading to poor quality of life and significant healthcare expenses. 11 The high prevalence of sarcopenia in older adults, combined with its detrimental consequences, warrants the need for effective prevention and management strategies. In SSc patients, addressing sarcopenia may improve their functional status and overall health outcomes, highlighting the importance of early screening and intervention. Healthcare professionals need to recognize the interplay between SSc and sarcopenia to provide optimal care for these patients.

In recent years, the presence of sarcopenia in SSc has garnered attention in several studies.<sup>4</sup>-<sup>7,12–16</sup> The documented prevalence of sarcopenia in SSc varies widely from 10.7% to 42% among different studies, which can be attributed to several factors. 4,5 Differences in diagnostic criteria and assessment methods utilized in various studies, such as those proposed by the European Working Group of Sarcopenia in Older People (EWGSOP)<sup>17,18</sup> and the Asian Working Group for Sarcopenia (AWGS), 19 can result in variations in the evaluation of muscle mass in patients. Furthermore, the influence of sarcopenia on the clinical features of SSc patients has been a topic of debate. For instance, Caimmi et al. 12 suggested that individuals with SSc and sarcopenia had a longer duration of disease; the longer disease duration means that patients live longer with the disease, while Siegert et al.<sup>6</sup> contradicted this claim and found no difference between sarcopenia and disease duration in SSc patients. Currently, no comprehensive systematic review or meta-analysis has examined sarcopenia in SSc. Therefore, we conducted a systematic review and meta-analysis to identify the diagnostic criteria for sarcopenia and evaluate the most reliable evidence on the prevalence of sarcopenia 

### Methods

### 17 Data sources and search strategy

This systematic review and meta-analysis was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guideline<sup>20</sup> and registered in PROSPERO (CRD42022368326). We systemically searched four electronic databases, including Embase, Medline, Web of Science, and the Cochrane Central Register of Controlled Trials, to identify all relevant articles relating to sarcopenia and SSc, without language

in SSc patients, as well as the effect of sarcopenia on the clinical features of SSc patients.

- 1 restrictions. Our search encompassed all records published from inception to May 24, 2023,
- 2 utilizing the following terms: 'systemic sclerosis', 'scleroderm\*', 'SSc', 'muscular atrophy',
- 3 'sarcopen\*' and 'myopen\*' (Supporting Information, Table S1-4). Additionally, we conducted
- 4 a manual search of the reference lists of the included articles to identify potential studies that
- 5 may have been overlooked by the principal search.

### 6 Inclusion and exclusion criteria

- 7 The following inclusion and exclusion criteria were employed for this systematic review and
- 8 meta-analysis: (1) studies conducted exclusively on adult patients (age >18 years) diagnosed
- 9 with SSc; (2) studies reporting the prevalence of sarcopenia in SSc patients; (3) studies defining
- sarcopenia as low muscle mass (LMM) plus low muscle strength (LMS), and/or low physical
- performance (LPP), or LMM alone; (4) studies measuring lean mass or muscle mass using one
- of the four main techniques: dual-energy X-ray absorptiometry (DXA), bioelectrical
- impedance analysis (BIA), magnetic resonance imaging (MRI) and computed tomography
- 14 (CT); and (5) observational studies. Conversely, the exclusion criteria were as follows: (1)
- repeated studies (defined as either identical data or identical articles); (2) animal studies, case
- 16 reports, reviews, editorials, comments, and letters.

### Outcomes

- 18 The main outcomes of this systematic review comprise two aspects: firstly, the prevalence of
- sarcopenia among patients with SSc, and secondly, the clinical features of patients with SSc
- 20 who suffer from sarcopenia compared to those who do not. These clinical features
- encompassed a range of factors, namely, the duration of disease, the quality of life assessed by
- 22 the Short Form-36 (SF-36) survey<sup>21</sup>, the pulmonary function (the forced vital capacity (FVC)

1 predicted value), and the C-relative protein level.

### 2 Study selection and data extraction

 After removing duplicates, the studies identified through the search strategy underwent eligibility assessment by two reviewers (X.T. and T.L.), who independently screened the titles and abstracts and assigned them to one of three categories: 'include,' 'exclude,' or 'maybe.' Subsequently, the full-text articles of those categorized as 'include' or 'maybe' were reviewed to arrive at a final selection, with any discrepancies between the reviewers resolved by a third reviewer (J.Y.). Two reviewers (X.T. and X.S.) independently extracted the following variables using a pre-defined data collection form: first author, publication year, country, study design, sample size, mean age, number of females, disease subtype, mean disease duration, SSc diagnostic criteria, sarcopenia diagnostic criteria, assessment method for detecting sarcopenia, and prevalence of sarcopenia. Additionally, we also collected data on clinical features in the form of mean ± standard deviation (SD). For those studies that were not expressed as mean ± SD, we performed data conversion with the method recommended by Luo et al.<sup>22</sup> and Wan et al.<sup>23</sup>

### Assessment of quality

Two authors (X.T. and T.J.) independently assessed the quality of the included studies using the Agency for Healthcare Research and Quality (AHRQ)<sup>24</sup> scale in cross-sectional studies. This tool consists of 11 questions, with a 'no' or 'unclear' receiving 0 points and a 'yes' receiving 1 point. Low-quality articles received scores of 0–3, moderate-quality scores of 4–7, and high-quality scores of 8–11. The Newcastle–Ottawa Scale (NOS) was used to judge the quality of the cohort study.<sup>25</sup> The NOS scoring system assigns points from 0 to 9. We assigned values

- 1 ranging from 0 to 3, 4 to 6, and 7 to 9 for low, moderate, and high-quality, accordingly. Any
- 2 discrepancies were resolved through discussion or consensus with a third author (J.Y.).

### 3 Statistical Analysis

- 4 The prevalence of sarcopenia in SSc patients was determined by calculating the proportion of
  - patients with sarcopenia in each study and conducting a meta-analysis of single proportions.
- 6 We performed this meta-analysis using Stata/SE (Version 12.0, StataCorp, Texas, USA).
- 7 Forest plots were used to illustrate the prevalence of sarcopenia, along with corresponding 95%
- 8 confidence intervals (CIs) for each study and the overall estimate. Clinical characteristics such
- 9 as disease duration, the SF-36 value, the FVC predicted value, and the CRP level from studies
- 10 that compared SSc patients with and without sarcopenia were also analyzed using Review
- 11 Manager (Version 5.4, The Cochrane Collaboration, Oxford, UK) and expressed as mean
- difference (MD) or standardized mean difference (SMD) with 95% CI. Heterogeneity across
- studies was assessed via the I<sup>2</sup> statistic, with values of 25% being considered low, 50%
- moderate, and 75% high.  $^{26}$  If  $I^2 > 50\%$ , a random-effects model was employed.
- 15 Subgroup analyses were conducted to investigate potential sources of heterogeneity, focusing
- on sarcopenia definition (1 vs >1 diagnostic criteria), disease subtype, and mean age (< 60 vs
- 17 ≥60 years). Meta-regressions were also conducted on sample size, mean age, percentage of
- 18 female patients, and duration of SSc. However, due to limited data on the clinical
- 19 characteristics of SSc patients with and without sarcopenia, subgroup analyses and meta-
- 20 regressions were not conducted. To evaluate the stability of pooled results, sensitivity analysis
- was performed by excluding one study at a time. Publication bias was evaluated using Egger's
- test<sup>27</sup>. Statistical significance was set at P < 0.05 for all analyses.

### 1 Patient and public involvement

2 None.

- 3 Results
- 4 Search results
- 5 A comprehensive search of databases yielded 4583 articles. After eliminating duplicates (n =
- 6 1523), the remaining 3060 titles and abstracts were screened. Subsequently, 25 relevant articles
- 7 underwent full-text reading, and 16 were excluded for reasons specified in the flow chart and
- 8 Table S5 in the supplement. Ultimately, 9 studies were eligible for inclusion in this meta-
- 9 analysis (Figure 1).
- 10 Study characteristics
- 11 Table 1 provides an overview of the characteristics of the studies included in this meta-analysis.
- A total of 815 SSc patients from 9 eligible studies<sup>4–7,12–16</sup> published between 2018 and 2022
- were included. The mean age of the patients ranged from 52.5 to 64.1 years, while the mean
- duration of SSc ranged from 6 to 12.8 years. The majority of the studies (8 out of 9) had a
- 15 cross-sectional design, 4-6,12-16 with one being a retrospective cohort study. The studies were
- 16 conducted in various regions, with five from Europe, 5-7,12,16 two from South America, 13,15 and
- 17 two from Asia.<sup>4,14</sup>
- 18 Risk of bias
- According to the AHRQ and NOS ratings, 8 of the eligible studies<sup>4–7,12,14–16</sup> were of moderate
- quality, with only one article<sup>13</sup> classified as high quality. (Table S7-8 in the supplement).
- 21 Methods used to assess sarcopenia
- Table 1 provides an overview of the diagnostic criteria used to evaluate sarcopenia across the

- 1 included studies. Among them, seven studies<sup>4–7,13,15,16</sup> employed EWGSOP criteria (5
- 2 EWGSOP2010 and 2 EWGSOP2019) while one<sup>14</sup> used AWGS criteria. Three studies<sup>5,7,12</sup>
- 3 solely relied on LMM for sarcopenia diagnosis, while six studies<sup>4,6,13-16</sup> utilized LMM
- 4 combined with LMS and/or LPP. The sarcopenia diagnostic criteria and cutoff values in the
  - studies are summarized in Table 2. Muscle mass was measured using dual-energy X-ray
- 6 absorptiometry in seven studies<sup>5,7,12–16</sup> and bioelectrical impedance analysis in two studies<sup>4,6</sup>.
- 7 Handgrip dynamometry was utilized to assess muscle strength in six studies<sup>4,6,13–16</sup>, while gait
- 8 speed (three studies<sup>14–16</sup>) and the short physical performance battery (SPPB) (two studies<sup>13,16</sup>)
- 9 were used to evaluate physical performance.

### 10 Sarcopenia prevalence

- 11 Overall sarcopenia prevalence
- 12 The nine studies included in this review reported the prevalence of sarcopenia in SSc patients,
- ranging from 10.7% to 42% (Table 1). The pooled prevalence of sarcopenia in patients with
- 14 SSc was estimated at 22% (95% CI 17%-28%), as shown in Figure 2.
- 15 Subgroup analysis of sarcopenia prevalence
- The prevalence of sarcopenia differed in studies that utilized a single criterion [LMM; 28% (95%)]
- 17 CI 16%-42%)] versus those that employed >1 criterion [LMM + LMS and/or LPP; 20% (95%)]
- 18 CI 15%-25%)], with no statistically significant difference noted (P = 0.234, Figure S1 in the
- supplement). Subgroup analysis based on disease subtype revealed that sarcopenia prevalence
- 20 in dcSSc [30% (95% CI 23%-37%)] was higher than that in lcSSc [23% (95% CI 12%-36%)],
- and the difference was not statistically significant (P = 0.339, Figure S2 in the supplement).
- The United Nations defines an older person as someone above the age of 60. Therefore, we

- also performed a subgroup analysis stratified by the mean age of the participants, with < 60
- 2 and  $\geq$  60 years as the cutoff points. The prevalence of sarcopenia was lower in patients younger
- 3 than 60 years [20% (95% CI 12%-29%)] vs those older than 60 years [24% (95% CI 17%-
- 4 32%)], but the difference was not of statistical significance (P = 0.539, Figure S3 in the
- 5 supplement).

- 6 <u>Meta-regression analyses</u>
- 7 The results of the meta-regression analyses indicated that there was no significant association
- between the prevalence of sarcopenia and sample size (P = 0.424), mean age of patients (P = 0.424)
- 9 0.532), the proportion of female patients (P = 0.449), or duration of SSc (P = 0.255). These
- 10 findings are summarized in Table S6 of the supplementary material.
- 11 Impact of sarcopenia on the clinical characteristics of SSc patients
- 12 <u>Duration of SSc</u>
- Data from a total of four studies comprising 511 patients were included in the meta-analysis of
- 14 SSc duration, which revealed that individuals with sarcopenia did not have a longer disease
- duration than those without sarcopenia [MD 2.97 (95% CI -0.13 to 6.08);  $I^2 = 90\%$ , Figure 3A].
- 16 Quality of life
- 17 The meta-analysis included two studies with a total of 191 patients, which provided data on the
- SF-36 value. The findings of the meta-analysis indicated that patients with sarcopenia had a
- lower SF-36 value compared to those without sarcopenia [MD -12.02 (95% CI -19.11 to -4.93);
- $I^2 = 71\%$ , Figure 3B], that is, having sarcopenia was associated with poorer quality of life
- 21 compared with those without sarcopenia.
- 22 Pulmonary function

- 1 The meta-analysis incorporated two studies involving a total of 320 patients that reported data
- 2 on the FVC predicted value. The results indicated that patients with sarcopenia did not have a
- 3 lower FVC predicted value than those without sarcopenia [MD -4.02 (95% CI -8.67 to 0.62);
- $I^2 = 0\%$ , Figure 3C]. Therefore, there was no significant difference in pulmonary function
- 5 between sarcopenia and non-sarcopenia patients.
- 6 <u>CRP level</u>
- 7 Data from two studies comprising 191 patients were analyzed to investigate the relationship
- 8 between sarcopenia and CRP level. The results showed that sarcopenia was associated with a
- 9 higher CRP level than no sarcopenia [SMD 0.67 (95% CI 0.35 to 1.00);  $I^2 = 0\%$ , Figure 3D].
- 10 Sensitivity and publication bias analysis
- 11 The sensitivity analysis revealed that the overall prevalence of sarcopenia was not significantly
- affected by any individual study (Figure S4 in the supplementary material). In addition, Egger's
- test suggested no publication bias in this review (P = 0.311, Figure S5 in the supplement).
- 14 Discussion
- **Primary results**
- In this meta-analysis encompassing nine studies, the pooled prevalence of sarcopenia among
- 17 815 patients diagnosed with systemic sclerosis (SSc) was estimated to be 22%, which was
- significantly greater than that in community-dwelling older adults.<sup>28</sup> Notably, SSc patients
- 19 diagnosed with sarcopenia had poorer quality of life and a higher CRP level, while no
- significant difference was noted for disease duration and FVC predicted value when compared
- 21 to patients without sarcopenia.
- 22 Mechanism basis

 Sarcopenia, a condition characterized by loss of muscle mass and function, can be ageassociated (primary sarcopenia) or secondary to chronic diseases, including malignant tumors and musculoskeletal diseases.<sup>29–31</sup> Compared with other chronic inflammatory rheumatic diseases, sarcopenia has not been extensively evaluated in SSc. Recently, some studies have focused on the presence of sarcopenia in SSc. Nevertheless, the pathogenesis of sarcopenia in SSc remains unclear. Possible mechanisms contributing to the development of sarcopenia in SSc include (1) malnutrition: gastrointestinal involvement is the most frequent internal complication of SSc<sup>32</sup>. Symptoms such as esophageal reflux, early satiety, nausea, and vomiting may lead to reduced caloric intake. 12 Additionally, fibrosis of the bowel wall and small intestine bacterial overgrowth can result in malabsorption of nutrients. Therefore, malnutrition is prevalent in SSc patients. One study in community-dwelling older adults demonstrated that malnutrition is an independent predictor of sarcopenia (OR: 2.42; 95% CI 1.04-5.60)<sup>33</sup>. (2) Oxidative stress and chronic inflammation: oxidative stress, which is an imbalance in oxidant and antioxidant levels, is commonly observed in SSc patients<sup>34</sup>. Increased oxidative stress disrupts the balance between the degradation and resynthesis of skeletal muscle proteins<sup>35</sup>. In addition, chronic low-grade inflammation is detrimental to skeletal muscle in humans<sup>36</sup>. Inflammatory cytokines, such as tumor necrosis factor-α and interleukin-6, have been reported to contribute to the pathogenesis of SSc<sup>37</sup>. These cytokines stimulate protein catabolism and suppress muscle synthesis, ultimately leading to muscle wasting<sup>38</sup>. (3) Physical inactivity: due to pain and joint involvement, physical inactivity is common in SSc patients<sup>39</sup>, leading to faster and greater muscle loss<sup>40</sup>. However, the mechanism of sarcopenia in SSc patients remains to be confirmed by future research.

### Interpretation of the results

This review offers unique insight into sarcopenia in patients with SSc. It describes the prevalence of sarcopenia in SSc patients and how it is impacted by the different definitions of sarcopenia. The varying prevalence of sarcopenia may be explained in part by the variety of definitions. However, there was no statistical difference between 1 and >1 diagnostic criteria. This might be due to the lack of robustness of the combined results as a result of the small number of studies using one diagnostic criterion. In addition, discrepancies in sarcopenia diagnostic cutoffs among the included studies may have resulted in differing sarcopenia prevalence. Furthermore, our meta-analysis indicated no statistically significant variation in the prevalence of sarcopenia between disease subtypes, which is consistent with the results of Sangaroon et al.<sup>14</sup> It is important to note that this conclusion needs to be interpreted with caution due to the limited number of studies that could be included in the analysis. Although sarcopenia commonly occurs as an age-related process in older individuals<sup>41</sup>, it becomes more common as people get older. Our meta-analysis demonstrated that the difference in the prevalence of sarcopenia was not statistically significant between the patients over 60 years old and the patients under 60 years old. Furthermore, patients younger than 60 years old all used >1 criterion to diagnose sarcopenia, which makes the prevalence of sarcopenia in young people even lower. This suggests that, despite the influence of age on the presence of sarcopenia, the illness itself is responsible for sarcopenia onset and progression in SSc patients. Therefore, rheumatologists should screen for sarcopenia even in young SSc patients. However, this conclusion must be confirmed by a large number of high-quality clinical studies.

Our meta-analysis also revealed that SSc patients diagnosed with sarcopenia had poorer quality

of life. On the one hand, involvement of the heart, lungs, and joints in SSc patients might result in diminished exercise capacity and decreased physical activity, making SSc patients vulnerable to sarcopenia. On the other hand, sarcopenia is associated with a variety of negative outcomes, including hospitalization, functional decline, falls, and death. Therefore, it should come as no surprise that SSc patients with sarcopenia have a higher risk of having a worse quality of life. Furthermore, individuals with SSc who had sarcopenia had higher CRP levels, according to our findings. This result is not surprising given that chronic inflammation is a known contributor to secondary sarcopenia. However, our review indicated that no significant difference was noted for disease duration or FVC predicted value between SSc patients with and without sarcopenia. According to the results of Caimmi et al, the longer the disease duration, the greater the risk of sarcopenia. This might be due to the minimal number of studies that could extract data, resulting in false negatives in the pooled study results. Therefore, large prospective cohort studies are required to confirm this conclusion.

### Clinical implications

 This meta-analysis provides a comprehensive evaluation of the prevalence, diagnostic criteria, and impact of sarcopenia in SSc patients, which has not been previously done. The results of this study provide an up-to-date estimation of the prevalence of sarcopenia, which can guide sample size calculations for future research. While sarcopenia has been relatively under-studied in SSc compared to other rheumatic diseases, our findings suggested that neither sarcopenia definition, disease subtype nor age affects the prevalence of sarcopenia. SSc patients with sarcopenia had poorer quality of life, according to our findings. Therefore, early identification and intervention of sarcopenic patients by clinicians is crucial. The high prevalence of

- 1 sarcopenia in SSc patients highlights the importance of early screening and management.
- 2 Standardized criteria for sarcopenia diagnosis are also essential in SSc patients to minimize
- 3 variations in prevalence. These findings have important implications for future research,
- 4 clinical practice, and policy development in managing sarcopenia in SSc patients, and can
- 5 potentially improve outcomes for these patients.

### 6 Strengths and weaknesses

- 7 This systematic review undertook a comprehensive and meticulous literature search to ensure
- 8 that all pertinent studies were included in the analysis. The selection of studies, data extraction,
- 9 and quality assessments were carried out independently by two reviewers, thereby enhancing
- the accuracy and reliability of the results. Subgroup analyses and meta-regression analyses
- 11 were also conducted to explore the possible sources of heterogeneity, while sensitivity and
- publication bias analyses were performed to ensure robust and dependable conclusions.
- Nevertheless, we must acknowledge certain limitations of our study. Firstly, since most of the
- 14 included studies were cross-sectional, it is impossible to establish a definitive causal
- relationship between sarcopenia and SSc. Nonetheless, this is a limitation inherent to the
- original literature and beyond our control. We, therefore, look forward to high-quality
- 17 prospective cohort studies to provide more conclusive evidence on this matter. Secondly, there
- was some heterogeneity among the included studies in terms of factors such as the definition
- of sarcopenia, measurement approaches, and diagnostic cut-offs. Moreover, most of the studies
- 20 had small sample sizes. Therefore, future studies should aim to use uniform diagnostic criteria
- 21 for sarcopenia and expand the sample size to improve the quality of research. Finally, even
- 22 though this review included studies from different continents (European, South America, and

### **Conclusions**

- 4 Our study conducted a comprehensive analysis and determined a notable prevalence of
  - sarcopenia in patients diagnosed with SSc. SSc patients with sarcopenia had a worse quality of
- 6 life and higher CRP levels, based on our findings. Given the detrimental impact of sarcopenia
- 7 on quality of life, future efforts aimed at early identification of sarcopenia in the clinical
- 8 assessment of patients with SSc may have significance.

### 9 Contributors

- 10 All authors conceived and designed this review; YJ, XPT, and JRY developed the search
- strategy; XPT and TPL screened studies; XPT and XYS extracted data; XPT and TTJ appraised
- study quality; XPT and NG conducted data analysis; XPT drafted the manuscript; all authors
- revised the manuscript for important intellectual content. JRY had full access to all the data in
- the study and takes responsibility for the integrity of the data and the accuracy of the data
- 15 analysis.

#### Funding

- 17 This study was supported by grants from the Chinese National Science & Technology Pillar
- Program (2020YFC2005600), Sichuan Science and Technology Program (2021YFS0136)
- 19 1·3·5 projects for disciplines of excellence–Clinical Research Incubation Project, West China
- 20 Hospital, Sichuan University (19HXFH012), National Clinical Research Center for Geriatrics,
- West China Hospital, Sichuan University (Z20192009) 1.3.5 project for disciplines of
- excellence, West China Hospital, Sichuan University (ZYJC21005).

### 1 Role of the Funder:

- 2 The funder of the study had no role in study design, data collection, data analysis, data
- 3 interpretation, or writing of the report.
- 4 Competing interests
  - None declared.
- 6 Patient and public involvement
- 7 Patients and/or the public were not involved in the design, or conduct, or reporting, or
- 8 dissemination plans of this research.
- 9 Patient consent for publication
- 10 Not required.
- 11 Ethics approval
- 12 Not applicable.
- 13 Data availability statement
- 14 The data are accessible upon reasonable request from the corresponding author.
- 15 Online supplementary material
- Additional supporting information may be found online in the Supporting Information section
- at the end of the article.

#### Reference

- 2 1. Denton CP, Khanna D. Systemic sclerosis. *The Lancet*. 2017;390:1685-1699.
- 3 2. Zhong L, Pope M, Shen Y, Hernandez JJ, Wu L. Prevalence and incidence of systemic
- 4 sclerosis: A systematic review and meta-analysis. *International Journal of Rheumatic*
- *Diseases*. 2019;22:2096-2107.
  - 3. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis):
  - classification, subsets and pathogenesis. *J Rheumatol*. 1988;15:202-205.
- 8 4. Sari A, Esme M, Aycicek GS, et al. Evaluating skeletal muscle mass with ultrasound in
- 9 patients with systemic sclerosis. *Nutrition*. 2021;84:110999.
- 10 5. Corallo C, Fioravanti A, Tenti S, Pecetti G, Nuti R, Giordano N. Sarcopenia in systemic
- sclerosis: the impact of nutritional, clinical, and laboratory features. *Rheumatol Int.*
- 12 2019;39:1767-1775.
- 13 6. Siegert E, March C, Otten L, et al. Prevalence of sarcopenia in systemic sclerosis:
- 14 assessing body composition and functional disability in patients with systemic sclerosis.
- *Nutrition*. 2018;55-56:51-55.
- 7. Paolino S, Goegan F, Cimmino MA, et al. Advanced microvascular damage associated
- with occurrence of sarcopenia in systemic sclerosis patients: Results from a retrospective
- 18 cohort study. *Clinical and Experimental Rheumatology*. 2020;38 Suppl 125(3):65-72.
- 19 8. Cuomo G, Santoriello C, Polverino F, Ruocco L, Valentini G, Polverino M. Impaired
- 20 exercise performance in systemic sclerosis and its clinical correlations. Scandinavian
- *Journal of Rheumatology*. 2010;39:330-335.
- 22 9. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on
- 23 definition and diagnosis. *Age Ageing*. 2010;39:412-423.
- 24 10. Papadopoulou SK, Tsintavis P, Potsaki G, Papandreou D. Differences in the Prevalence
- of Sarcopenia in Community-Dwelling, Nursing Home and Hospitalized Individuals. A
- Systematic Review and Meta-Analysis. *J Nutr Health Aging*. 2020;24:83-90.
- 27 11. Cruz-Jentoft AJ, Sayer AA. Sarcopenia. *The Lancet*. 2019;393:2636-2646.
- 28 12. Caimmi C, Caramaschi P, Venturini A, et al. Malnutrition and sarcopenia in a large cohort
- of patients with systemic sclerosis. *Clin Rheumatol*. 2018;37:987-997.
- 30 13. Hax V, do Espírito Santo RC, Dos Santos LP, et al. Practical screening tools for
- 31 sarcopenia in patients with systemic sclerosis. *PLoS ONE*. 2021;16(1):e0245683.
- 32 14. Sangaroon A, Foocharoen C, Theerakulpisut D, et al. Prevalence and clinical association
- of sarcopenia among Thai patients with systemic sclerosis. *Sci Rep.* 2022;12:18198.

- 1 15. Rincón IDR, Alak M, Alsina G, et al. Sarcopenia in systemic sclerosis. *Arthritis and Rheumatology*. 2019;71(S10):2957-2958.
- 3 16. Efremova AO, Toroptsova NV, Nikitinskaya OA, et al. The frequency of sarcopenia and factors associated with muscle mass in women with systemic scleroderma (Pilot Study).
- 5 Osteoporosis International. 2022;32(S1):S409.
- 6 17. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on
- 7 definition and diagnosis: Report of the European Working Group on Sarcopenia in Older
  - People. Age Ageing. 2010;39:412-423.
- 9 18. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. *Age Ageing*. 2019;48:16-31.
- 19. Chen LK, Liu LK, Woo J, et al. Sarcopenia in Asia: consensus report of the Asian
- Working Group for Sarcopenia. *Journal of the American Medical Directors Association*.
- 13 2014;15(2):95-101.
- 20. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;372:n71.
- guideline for reporting systematic reviews. Divio. 2021,572.1171.
- 16 21. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I.
- 17 Conceptual framework and item selection. *Medical care*. 1992;30(6):473-483.
- 18 22. Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample
- size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res.
- 20 2018;27:1785-1805.
- 21 23. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from
- the sample size, median, range and/or interquartile range. BMC Med Res Methodol.
- 23 2014;14:135.
- 24 24. Zeng X, Zhang Y, Kwong JSW, et al. The methodological quality assessment tools for
- preclinical and clinical studies, systematic review and meta-analysis, and clinical practice
- 26 guideline: a systematic review. J Evid Based Med. 2015;8:2-10.
- 27 25. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the
- quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol*. 2010;25:603-605.
- 29 26. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-
- analyses. *BMJ*. 2003;327:557-560.
- 27. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a
- simple, graphical test. *BMJ*. 1997;315:629-634.
- 33 28. Simsek H, Meseri R, Sahin S, et al. Prevalence of sarcopenia and related factors in
- community-dwelling elderly individuals. *Saudi Med J.* 2019;40:568-574.

- Neuroblastoma. *Journal of Surgical Research*. 2019;236:101-105.
- 30. Matsunaga T, Miyata H, Sugimura K, et al. Prognostic Significance of Sarcopenia and
- Systemic Inflammatory Response in Patients With Esophageal Cancer. Anticancer Res.
- 2019;39:449-458.

- 31. Laurent MR, Dedeyne L, Dupont J, Mellaerts B, Dejaeger M, Gielen E. Age-related bone loss and sarcopenia in men. Maturitas. 2019;122:51-56.
- 32. Clements PJ, Becvar R, Drosos AA, Ghattas L, Gabrielli A. Assessment of gastrointestinal involvement. :4.
- 33. Kurose S, Nishikawa S, Nagaoka T, et al. Prevalence and risk factors of sarcopenia in
- community-dwelling older adults visiting regional medical institutions from the Kadoma
- Sarcopenia Study. Sci Rep. 2020;10:19129.
- 34. Doridot L, Jeljeli M, Chêne C, Batteux F. Implication of oxidative stress in the
- pathogenesis of systemic sclerosis via inflammation, autoimmunity and fibrosis. Redox
- Biology. 2019;25:101122.
- 35. Meng SJ, Yu LJ. Oxidative Stress, Molecular Inflammation and Sarcopenia. *International* Journal of Molecular Sciences. 2010;11:1509-1526.
- 36. Howard C, Ferrucci L, Sun K, et al. Oxidative protein damage is associated with poor
- grip strength among older women living in the community. Journal of Applied Physiology.
- 2007;103:17-20.
- 37. Shima Y. Cytokines Involved in the Pathogenesis of SSc and Problems in the Development of Anti-Cytokine Therapy. Cells. 2021;10:1104.
- 38. Bano G, Trevisan C, Carraro S, et al. Inflammation and sarcopenia: A systematic review and meta-analysis. Maturitas. 2017;96:10-15.
- 39. Liem SIE, Meessen JMTA, Wolterbeek R, et al. Physical activity in patients with systemic
- sclerosis. Rheumatol Int. 2018;38:443-453.
- 40. Roubenoff R. Sarcopenia and its implications for the elderly. Eur J Clin Nutr.
- 2000;54:S40-S47.
- 41. Cruz-Jentoft AJ, Sayer AA. Sarcopenia. The Lancet. 2019;393:2636-2646.
- 42. Tsekoura M, Kastrinis A, Katsoulaki M, Billis E, Gliatis J. Sarcopenia and Its Impact on
- Quality of Life. Adv Exp Med Biol. 2017;987:213-218.
- 43. Beaudart C, Rizzoli R, Bruyère O, Reginster J-Y, Biver E. Sarcopenia: burden and
- challenges for public health. Arch Public Health. 2014;72:45.

- 44. Wang C, Bai L. Sarcopenia in the elderly: basic and clinical issues. *Geriatr Gerontol Int.* 2012;12:388-396.
- 3 45. Baumgartner RN, Koehler KM, Gallagher D, et al. Epidemiology of sarcopenia among the elderly in New Mexico. *Am J Epidemiol*. 1998;147:755-763.
- 46. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype.
   J Gerontol A Biol Sci Med Sci. 2001;56:M146-156.
- 47. Lauretani F, Russo CR, Bandinelli S, et al. Age-associated changes in skeletal muscles
   and their effect on mobility: an operational diagnosis of sarcopenia. *J Appl Physiol* (1985).
   2003;95:1851-1860.
- 48. Gould H, Brennan SL, Kotowicz MA, Nicholson GC, Pasco JA. Total and appendicular
   lean mass reference ranges for Australian men and women: the Geelong osteoporosis
   study. *Calcif Tissue Int.* 2014;94:363-372.
- 49. Dodds RM, Syddall HE, Cooper R, et al. Grip strength across the life course: normative data from twelve British studies. *PLoS One*. 2014;9:e113637.
- Pavasini R, Guralnik J, Brown JC, et al. Short Physical Performance Battery and all-cause
   mortality: systematic review and meta-analysis. *BMC Med*. 2016;14:215.
- 17 51. Cesari M, Kritchevsky SB, Newman AB, et al. Added value of physical performance
   18 measures in predicting adverse health-related events: results from the Health, Aging And
   19 Body Composition Study. *J Am Geriatr Soc.* 2009;57:251-259.
- 52. Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. *JAMA*.
   21 2011;305:50-58.
- 53. Chen L-K, Woo J, Assantachai P, et al. Asian Working Group for Sarcopenia: 2019
   Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc.
   2020;21:300-307.e2.

6	Tab	le 1 Chara	cteristics of the i	ncluded st	tudies					on 5 g for			
10 11 12 13		Country	Study design	Sample size	Mean age(years)	Female, n	Disease subtype	Disease duration (years)	SSc diagnostic criteria	Marcopenia Marchenostic Enseignement Su Luses related to text		Prevalence sarcopenia of	of
14 15 16					6					baded fro perieur ( and dat		Total,n(%	Diffuse,n( %)
17 18 19		Italy Germany	Cross-sectional study Cross-sectional	140	64	118	limited 97 diffuse 43	12.8	2013 ACR/EULAR	m Atp://k ABES) . a mining,	LMM (DXA)	29(20.7%)	11(7.9%)
21 22 23		Germany	study	129	60	118	(P/	7	2013 ACR/EULAR	m Mitp://bmjope0.bgj.com/ or.Juge ABES) . W (2 w (2) W (2) W (2)	( BIA ) LMS	29(22.5%)	-
24 25 26 27									ACR/EULAR	(2) (2) (2) (2) (2) (2) (2) (3) (4) (4) (5) (6) (7) (7) (7) (7) (7) (7) (7) (7) (7) (7	( HGS )		
29 30		Italy Argentina	Cross-sectional study Cross-sectional	62	62	54	limited 50 diffuse 12	8	2013 ACR/EULAR	WGSOP techno	LMM (DXA)	26(42%)	4(6.4%)
31 32 33 34	$(2019)^{15}$	Ü	study	27	52.5	20	limited 16	7.8	2013	und 0) (2 Re 8, 2025 at Agger technologies. EW ger	( DXA ) LMS	9(33.3%)	3(11.1%)
35 36 37 38							diffuse 11		ACR/EULAR	(20cc Biblio	( HGS ) LPP (4mGS)		, , ,
39 40 41							23			Bibliographique de	Li r (4iiiO3)		
42 43				For	oeer review only	· - http://bmj	jopen.bmj.com	/site/about	:/guidelines.xhtr	e de -			

Pa	ge 25 of 54						BMJ Open			bmjopen			
1 2 3 4_										bmjopen-2023-078034 copen San San in the copyright, including fr			
_	First author and year	Country	Study design	Sample size	Mean age(years)	Female,	Disease subtype	Disease duration (years)	SSc diagnostic criteria	OP O	a Criteria (assessment method detecting sarcopenia)	Prevalence sarcopenia of	of
12 13										Downlo ent Sul to text		Total,n(%	Diffuse,n( %)
1 <del>4</del> 15 16	Paolino (2020) <sup>7</sup>	Italy	Retrospective cohort study	43	64.1	36	-	10.2	2013 ACR/EULAR	The Position of the Control of the C	LMM (DXA)	10(23.3%)	-
17 18	Hax $(2021)^{13}$	Brazil	Cross-sectional							om ht	LMM		
19 20			study						2013	EWESOP	(DXA)		
21 22				94	60.5	87	0//	12.5	ACR/EULAR	trae(20219)	LMS	15(15.9%)	-
23 24										n.bmj ning, a	(HGS)		
25 26 27		Turkey	Cross-sectional							.com/ on and simil	LPP (SPPB) LMM		
28 29			study							ar tegwegsop	( BIA )		
30 31				93	52.6	86	-	10.7	1980ACR	hno(2010)	LMS	10(10.7%)	-
32 33										25 at ogies.	(HGS)		
34 35 36 37 38	Efremova (2022) <sup>16</sup>	Russia	Cross-sectional study	47	53.9	47	limited 29 diffuse 18	6	2013 ACR/EULAR	Agensop EWere Belg 9 )	LMM (DXA) LMS (HGS and Chair rising test)	10(21.3%)	6(12.8%)
39 40 41 42							24			iographique de l			
42 43 44 45				Forp	oeer review onl	y - http://bm	jopen.bmj.com	/site/abou	t/guidelines.xht	ml —			




Table 2 Criteria and cutoff points used to detect sarcopenia in each study

	<u> </u>	
First author	Sarcopenia	Cutoff points
and year	diagnostic criteria	
Caimmi	SMI	LMM: ASM/height2 < 7.26 kg/m <sup>2</sup> for men
$(2018)^{12}$		and < 5.50 kg/m <sup>2</sup> for women. <sup>45</sup>
Siegert (2018) <sup>6</sup>	EWGSOP (2010)	LMM: ALM/height2 < 7.26 kg/m2 for men
	O,	and <5.50 kg/m2 for women. <sup>45</sup>
		LMS: BMI ≤ 24, HGS ≤ 29 kg; 24.1 ≤ BMI
		$\leq$ 26, HGS $\leq$ 30 kg; 26.1 $\leq$ BMI $\leq$ 28, HGS $\leq$
		30 kg; BMI > 28, HGS ≤ 32 kg for men.
		BMI $\leq 23$ , HGS $\leq 17$ kg; $23.1 \leq$ BMI $\leq 26$ ,
		$HGS \le 17.3 \text{ kg}; 26.1 \le BMI \le 29, HGS \le 18$
		kg; BMI > 29, HGS $\leq$ 21 kg for women. <sup>46</sup>
Corallo (2019) <sup>5</sup>	EWGSOP (2010)	LMM: RSMI < 7.26 kg/m2 for men and < 5.50
		kg/m2 for women. <sup>45</sup>
Rincon (2019) <sup>15</sup>	EWGSOP (2010)	LMM: RSMI < 7.26 kg/m2 for men and < 5.50
		kg/m2 for women. <sup>45</sup>
		LMS: HGS< 30 kg for men and< 20 kg for
		women. <sup>47</sup>
		LPP: GS< 0.8 m/s (both genders). <sup>47</sup>
Paolino (2020 )	EWGSOP (2010)	LMM: RSMI < 7.26 kg/m2 for men and < 5.50

First author	Sarcopenia	Cutoff points
and year	diagnostic criteria	
7		kg/m2 for women. <sup>45</sup>
Hax (2021)	EWGSOP (2019)	LMM: ASMI < 7.0 kg/m <sup>2</sup> for men and < 5.5
		kg/m <sup>2</sup> for women. <sup>48</sup>
		LMS: HGS < 27 kg for men and < 16 kg for
	0,	women. <sup>49</sup>
		LPP: SPPB ≤ 8 point score. <sup>50</sup>
Sari (2021) <sup>4</sup>	EWGSOP (2010)	LMM: ASMI < 7.26 kg/m2 for men and <5.50
		kg/m2 for women. <sup>45</sup>
		LMS: BMI ≤ 24, HGS ≤ 29 kg; 24.1 ≤ BMI
		$\leq$ 26, HGS $\leq$ 30 kg; 26.1 $\leq$ BMI $\leq$ 28, HGS $\leq$
		30 kg; BMI > 28, HGS ≤ 32 kg for men.
		$BMI \le 23, HGS \le 17 \text{ kg}; 23.1 \le BMI \le 26,$
		$ HGS \le 17.3 \text{ kg}; 26.1 \le BMI \le 29, HGS \le 18$
		kg; BMI > 29, HGS $\leq$ 21 kg for women. <sup>46</sup>
Efremova	EWGSOP (2019)	LMM: ASMI < 7.0 kg/m <sup>2</sup> for men and < 5.5
$(2022)^{16}$		kg/m <sup>2</sup> for women. <sup>48</sup>
		LMS: HGS < 27 kg for men and < 16 kg for
		women. <sup>49</sup> or Chair stand > 15 s for five
		rises. <sup>51</sup>

First author	Sarcopenia	Cutoff points
and year	diagnostic criteria	
		LPP: GS $\leq$ 0.8 m/s. <sup>52</sup> or SPPB $\leq$ 8 point
		score. <sup>50</sup>
Sangaroon	AWGS (2019)	LMM: ASMI < 7.0 kg/m <sup>2</sup> for men and < 5.4
(2022)14		kg/m <sup>2</sup> for women. <sup>53</sup>
	O,	LMS: HGS < 28 kg for men and < 18 kg for
		women. <sup>53</sup>
		LPP: GS< 1 m/s (both genders). <sup>53</sup>

SMI, Skeletal Muscle Mass Index; ASM, appendicular skeletal muscle mass; ALM, appendicular lean mass; RSMI, Relative Skeletal Muscle Mass Index; ASMI, Appendicular Skeleton Muscle Index; SPPB, Short Physical Performance Battery; GS, gait speed.

Figure 1 The flow chart of the literature selection






Figure 2 The pooled prevalence of sarcopenia in SSc patients



CI, confidence interval; ES, effect size (prevalence %); I², I² heterogeneity statistic.

Random effects model used for analysis.



#### A Effect of sarcopenia on disease duration (years) of SSc patients

	Sar	Sarcopenia No sarcopenia						Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Caimmi 2018	16	8	29	12	7	111	22.1%	4.00 [0.81, 7.19]	
Corallo 2019	11.86	2.52	26	6	1.42	36	27.9%	5.86 [4.79, 6.93]	-
Sangaroon 2022	6.64	5.17	41	6.11	5.31	139	26.3%	0.53 [-1.28, 2.34]	-
Siegert 2018	9.45	6.42	29	8.12	6.8	100	23.7%	1.33 [-1.36, 4.02]	-
Total (95% CI)			125			386	100.0%	2.97 [-0.13, 6.08]	
Heterogeneity: Tau2 =	= 8.69; C	hi² = 2	9.30, di	f = 3 (P <		-10 -5 0 5 10			
Test for overall effect	Z= 1.88	B (P = 0	0.06)						Favours [Sarcopenia] Favours [No sarcopenia]

#### B Effect of sarcopenia on quality of life (SF-36 value) in SSc patients

	Sa	rcopeni	a	No s	arcope	nia		Mean Difference	Mean Difference				
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI				
Corallo 2019	35.74	3.53	26	50.57	4.73	36	62.4%	-14.83 [-16.89, -12.77]					
Siegert 2018	40.9	18.53	29	48.26	17.61	100	37.6%	-7.36 [-14.94, 0.22]	-				
Total (95% CI)			55			136	100.0%	-12.02 [-19.11, -4.93]					
Heterogeneity: Tau <sup>2</sup> =	19.88;	Chi <sup>2</sup> = 3.	48, df=	1 (P =	10 6 0 6 10								
Test for overall effect:	Z = 3.32	P = 0.0	0009)						Favours [Sarcopenia] Favours [No sarcopenia]				

#### C Effect of sarcopenia on pulmonary fuction (FVC predicted value) in SSc patients

	Sarcopenia No sarcopenia					nia		Mean Difference	Mean Difference			
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI			
Caimmi 2018	99	26	29	104	23	111	20.0%	-5.00 [-15.39, 5.39]	<del></del>			
Sangaroon 2022	65.85	14.89	41	69.63	15.03	139	80.0%	-3.78 [-8.98, 1.42]	-			
Total (95% CI)			70			250	100.0%	-4.02 [-8.67, 0.62]	•			
Heterogeneity: Chi <sup>2</sup> : Test for overall effect				-20 -10 0 10 20								
rest for overall effect	Test for overall effect: Z = 1.70 (P = 0.09)								Favours (Sarcopenia) Favours (No sarcopenia)			

### D Effect of sarcopenia on CRP in SSc patients

	Sar	copen	ia	No s	arcope	nia		Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Siegert 2018	12.66	21	29	4.64	11.35	100	61.3%	0.57 [0.15, 0.99]	
Corallo 2019	1.63	0.76	26	1.11	0.47	36	38.7%	0.84 [0.32, 1.37]	
Total (95% CI)			55			136	100.0%	0.67 [0.35, 1.00]	•
Heterogeneity: Chi2=	0.65, df	= 1 (P	= 0.42)	$     ^2 = 09$	6				-2 -1 0 1 2
Test for overall effect	Z = 4.03	(P < 0	).0001)						Favours [Sarcopenia] Favours [No sarcopenia]

## Sarcopenia in Systemic Sclerosis: Prevalence and Impact - A Systematic Review

### and Meta-analysis

- 1. Table S1 Search strategy by Medline via Ovid SP
- 2. Table S2 Search strategy by Embase via Ovid SP
- 3. Table S3 Search strategy by Web of Science
- 4. Table S4 Search strategy by Cochrane Central Register of Controlled Trials via
  Ovid SP
- 5. Table S5 The reasons for the exclusion of full-text articles
- 6. Table S6 Meta-regression analyses of sarcopenia prevalence
- 7. Table S7 ARHQ Methodology Checklist for Cross-Sectional Study
- 8. Table S8 Newcastle-Ottawa Scale for Cohort study
- 9. Figure S1 Prevalence of sarcopenia by criteria
- 10. Figure S2 Prevalence of sarcopenia by disease subtype
- 11. Figure S3 Prevalence of sarcopenia by mean age
- 12. Figure S4 Sensitivity analysis
- 13. Figure S5 Egger's test for publication bias

# Table S1 Search strategy by Medline via Ovid SP

- 1. exp Scleroderma, Systemic/
- 2. ((Systemic or general\* or diffus\* or progress\* or Limit\*) adj3 sclerosis).mp.
- 3. scleroderm\*.tw.
- 4. SSc.tw.
- 5. 1 or 2 or 3 or 4
- 6. exp muscular atrophy/
- 7. (sarcopen\* or myopen\* or dynapon\* or amyotroph\* or myoatroph\* or myophagis\* or myodegenerat\*).mp.
- 8. ((muscle or muscular) adj5 (atroph\* or wast\* or weak\* or loss\* or mass or degenerat\*)).ti,ab.
- 9. 6 or 7 or 8
- 10. 5 and 9
- 11. exp animals/ not humans.sh.
- 12. 10 not 11

# Table S2 Search strategy by Embase via Ovid SP

- 1. exp systemic sclerosis/
- 2. ((Systemic or general\* or diffus\* or progress\* or Limit\*) adj3 sclerosis).mp.
- 3. scleroderm\*.tw.
- 4. SSc.tw.

- 5. 1 or 2 or 3 or 4
- 6. exp muscle atrophy/
- 7. (sarcopen\* or myopen\* or dynapon\* or amyotroph\* or myoatroph\* or myophagis\* or myodegenerat\*).mp.
- 8. ((muscle or muscular) adj5 (atroph\* or wast\* or weak\* or loss\* or mass or degenerat\*)).ti,ab.
- 9. 6 or 7 or 8
- 10. 5 and 9
- 11. exp animal/
- 12. human/
- 13. 11 not 12
- 14. 10 not 13

## Table S3 Search strategy by Web of Science

Topic= (((Systemic or general\* or diffus\* or progress\* or Limit\*) near/3 sclerosis) or sclerodem or ssc) and (sarcopen\* or myopen\* or dynapon\* or amyotroph\* or myoatroph\* or myophagis\* or myodegenerat\* or ((muscle or muscular) near/5 (atroph\* or wast\* or weak\* or loss\* or mass or degenerat\*)))

# Table S4 Search strategy by Cochrane Central Register of Controlled Trials via

#### **Ovid SP**

- 1. exp Scleroderma, Systemic/
- 2. ((Systemic or general\* or diffus\* or progress\* or Limit\*) adj3 sclerosis).mp.
- 3. scleroderm\*.tw.
- 4. SSc.tw.
- 5. 1 or 2 or 3 or 4
- 6. exp muscular atrophy/
- 7. (sarcopen\* or myopen\* or dynapon\* or amyotroph\* or myoatroph\* or myophagis\* or myodegenerat\*).mp.
- 8. ((muscle or muscular) adj5 (atroph\* or wast\* or weak\* or loss\* or mass or degenerat\*)).ti,ab.
- 9. 6 or 7 or 8
- 10. 5 and 9

Table S5 The reasons for the exclusion of full-text articles

Study	Reason for the exclusion
Norman (2014)	Repeated study
Siegert (2014)	Repeated study
Caimmi (2017)	Repeated study
March (2017)	Repeated study
Doerfler (2017)	Intervention study
Paolino (2018)	Repeated study
Radic (2018)	Not reported sarcopenia prevalence data
	in SSc patients
Remolina (2019)	Repeated study
Sari (2019)	Repeated study
Veronica (2019)	Repeated study
Hax (2020)	Repeated study
Santo (2020)	Repeated study
Sangaroon (2020)	Repeated study
Peterson (2020)	Not reported sarcopenia prevalence data
	in SSc patients
Efremova (2021)	Repeated study
Sorokina (2022)	Not reported sarcopenia prevalence data
	in SSc patients

Variables	Coefficient	SE	P value	CI-Lower	CI-Upper
Sample size	-0.0022	0.0026	0.424	-0.0083	0.0039
Average age	0.0210	0.0319	0.532	-0.0545	0.0965
Proportion of	-1.0603	1.3233	0.449	-4.1893	2.0687
female					
Duration of	-0.0606	0.0488	0.255	-0.1760	0.0549
SSc					

Table S7 ARHQ Methodology Checklist for Cross-Sectional Study

Study	Ite	Ite	Ite	Ite	Ite	Ite	Ite	Ite	Ite	Ite	Ite	Total
	m 1	m 2	m 3	m 4	m 5	m 6	m 7	m 8	m 9	m	m	Score
										10	11	
Caimmi (2018)	Yes	Yes	Yes	Yes	Unc	Yes	No	No	Unc	Yes	No	6
					lear				lear			
Siegert (2018)	Yes	Yes	Unc	Yes	Unc	Yes	No	No	No	Yes	No	5
			lear		lear							
Corallo (2019)	Yes	Yes	Yes	Yes	Unc	Yes	No	No	No	Yes	No	6
					lear							
Rincon (2019)	Yes	Yes	Unc	Unc	Unc	Yes	No	No	No	Yes	No	4
			lear	lear	lear							
Hax (2021)	Yes	Yes	Yes	Yes	Unc	Yes	Yes	No	Yes	Yes	No	8
					lear							

Sari (2021)	Yes	Yes	Yes	Yes	Unc	Yes	No	No	No	Yes	No	6
					lear							
Efremova	Unc	Yes	Unc	Unc	Unc	Yes	No	No	No	Yes	No	3
(2022)	lear		lear	lear	lear							
Sangaroon	Yes	Yes	Yes	Yes	Unc	Yes	No	No	No	Yes	No	6
(2022)					lear							


- Item 1. Define the source of information (survey, record review)
- Item 2. List inclusion and exclusion criteria for exposed and unexposed subjects (cases and controls) or refer to previous publications
- Item 3. Indicate time period used for identifying patients

- Item 4. Indicate whether or not subjects were consecutive if not population-based
- Item 5. Indicate if evaluators of subjective components of study were masked to other aspects of the status of the participants
- Item 6. Describe any assessments undertaken for quality assurance purposes (e.g., test/retest of primary outcome measurements)
- Item 7. Explain any patient exclusions from analysis
- Item 8. Describe how confounding was assessed and/or controlled
- Item 9. If applicable, explain how missing data were handled in the analysis
- Item 10. Summarize patient response rates and completeness of data collection
- Item 11. Clarify what follow-up, if any, was expected and the percentage of patients for which incomplete data or follow-up was obtained

# **Table S8 Newcastle-Ottawa Scale for Cohort study**


Гable S8	Newcastle-Ottawa S	cale for Col	nort study	BMJ Open		bmjopen-2023-078034 on 5 March 2024. Down Enseignement Side by copyright, including for uses related to teach to be a copyright.			
Study	Selection	<b>**</b>			Comparability	Outcomen			Total
	Representativeness of the exposed cohort	Selection of the non- exposed cohort	Ascertainment of exposure	Demonstration that outcome of interest was not present at start of study	Comparability of cohorts on the basis of the design or analysis	Assessment of outwarf (A	Was follow-up long enough for outcomes to occur	Adequacy of follow up of cohorts	Score
Paolino (2020)	0	1	1	0	10,	1 lining, au	0	0	4
					0	n http://bmjopen.bmj.com/ on June 8, 2025 at Agence Bibliographique de I BES) . mining, Al training, and similar technologies.			
		Forp	oeer review only - ht	ttp://bmjopen.bmj.co	om/site/about/guideli	graphique de l nes.xhtml			

Figure S1 Prevalence of sarcopenia by criteria



ES = effect size (prevalence);  $I^2 = I^2$  heterogeneity statistic. A random effects model was used for analysis, and there was no significant difference between subgroups (P = 0.234).

Figure S2 Prevalence of sarcopenia by disease subtype



ES = effect size (prevalence);  $I^2 = I^2$  heterogeneity statistic. The random effects model was used for the analysis, and there was no significant difference between the subgroups (P = 0.339).





Figure S3 Prevalence of sarcopenia by mean age



ES = effect size (prevalence);  $I^2 = I^2$  heterogeneity statistic. The random effects model was used for the analysis, and there was no significant difference between the subgroups (P = 0.539).

Figure S4 Sensitivity analysis







Figure S5 Egger's test for publication bias







# PRISMA 2020 Checklist

ge 53 of 54		BMJ Open BMJ Open	
PRISM	1A 20	by copyrigh 20 Checklist	
Section and Topic	Item #	Checklist item	Location where item is reported
TITLE		9 0	
Title	1	Identify the report as a systematic review.	Pg. 1, lines 1-2
ABSTRACT		IS EN CONTROL OF THE	
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	Pg. 2
INTRODUCTION		ner ate	
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	Pg. 5, lines 1-11
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	Pg. 5, lines 13-15
METHODS		ο C C G G G G G G G G G G G G G G G G G	
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	Pg. 6, lines 6-16
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted identify studies. Specify the date when each source was last searched or consulted.	Pg. 5, lines 18-22; Pg. 6, lines 1-5
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used	Table S1-4
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how magy reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	Pg. 7, lines 3-8
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each epot, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	Pg. 7, lines 8-15
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with act outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which study were sought (e.g. for all measures).	Pg. 6, lines 18-22
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, <b>x</b> und g sources). Describe any assumptions made about any missing or unclear information.	Table 1 and Figure 3
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	Pg. 7, lines 17-22; Pg. 8 lines 1-2
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	Pg. 8, lines 6-12
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	Figure 2-3
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing sumbary statistics, or data conversions.	Pg. 7, lines 13-15
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	Pg. 8, lines 6-8
	13d	Describe any methods used tesynthesize results tand/brovide จากสาดเกลาอาร์ต เกลาอาร์ต	Pg. 8, lines

Page 54 of 54



# PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Locatio where it is repor
		model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) we deduced by the presence and extent of statistical heterogeneity, and software package(s) we deduced by the presence and extent of statistical heterogeneity.	4-12
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup and alyais, meta-regression).	Pg. 8, lir 15-18
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	Pg. 8, lii 20-21
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting 高級).	Pg. 8, li 21-22
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	None
RESULTS		and	
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the review, ideally using a flow diagram.	Figure
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	Figure Table S
Study characteristics	17	Cite each included study and present its characteristics.	Table 1
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	Table s
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	Figure Figure
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	Figure Figure
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	Pg. 10, lines 1 Pg.11, 1-5
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	Figure 3, Tabl
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	Pg. 12, lines 1 Figure
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis asses	Pg. 12 lines 1
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	None
DISCUSSION			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.  For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	Pg. 14, lines 1- Pg. 15,

cted by copyrigh



# PRISMA 2020 Checklist

3 4 5	Section and Topic	Item #	Checklist item	Location where item is reported
6			ling o	lines 1-13
7 8		23b	Discuss any limitations of the evidence included in the review.	Pg. 16, lines 17-20
9 10 11 12		23c	Discuss any limitations of the review processes used.  se s related  se s related	Pg. 16, lines 13-22; Pg.17 lines 1-2
13 14 15 16		23d	Discuss implications of the results for practice, policy, and future research.  to the formula of the results for practice, policy, and future research.  to the formula of the results for practice, policy, and future research.	Pg. 15, lines 15-22; Pg. 16 lines 1-5
17	OTHER INFORMA	TION	du f	
18 19	Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the register was not registered.	Pg. 5, lines 18-20
20 21		24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	Pg. 5, lines 18-20
22		24c	Describe and explain any amendments to information provided at registration or in the protocol.	None
23 24 25 26	Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the spinion of the spinion of the funders or sponsors in the spinion of the sp	Page 17, lines 17-22; Pg. 18 lines 1-3
27 28	Competing interests	26	Declare any competing interests of review authors.	Page 18, lines 4-5
29 30 31	Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	Table 1, Figure 2-3, Figure S1-3
32 33 34 35 36 37 38 39 40 41 42 43 44 45	From: Page MJ, McKe	enzie JE,	Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systems of Pormore information, visit: <a href="http://www.prisma-statement.org/">http://www.prisma-statement.org/</a> For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	0.1136/bmj.n71
46 47				

# **BMJ Open**

# Sarcopenia in Systemic Sclerosis: Prevalence and Impact - A Systematic Review and Meta-analysis

Geriatrics; Sichuan University West China Hospital, National Clinical Research Center for Geriatrics Lin, Taiping; Sichuan University West China Hospital, Department of Geriatrics; Sichuan University West China Hospital, National Clinical Research Center for Geriatrics Ju, Yuan; Sichuan University, Sichuan University library Shu, Xiaoyu; Sichuan University West China Hospital, Department of Geriatrics; Sichuan University West China Hospital, National Clinical Research Center for Geriatrics Jiang, Tingting; Sichuan University West China Hospital, Department of Geriatrics; Sichuan University West China Hospital, National Clinical Research Center for Geriatrics Ge, Ning; Sichuan University West China Hospital, Department of Geriatrics; Sichuan University West China Hospital, Department of Geriatrics; Sichuan University West China Hospital, Department of Geriatrics; Sichuan University West China Hospital, National Clinical Research Center for Geriatrics	Journal:	BMJ Open
Date Submitted by the Author:  Complete List of Authors:  Tu, Xiangping; Sichuan University West China Hospital, Department of Geriatrics; Sichuan University West China Hospital, National Clinical Research Center for Geriatrics Lin, Taiping; Sichuan University West China Hospital, Department of Geriatrics; Sichuan University West China Hospital, National Clinical Research Center for Geriatrics Ju, Yuan; Sichuan University, Sichuan University library Shu, Xiaoyu; Sichuan University West China Hospital, Department of Geriatrics; Sichuan University West China Hospital, National Clinical Research Center for Geriatrics Jiang, Tingting; Sichuan University West China Hospital, Department of Geriatrics; Sichuan University West China Hospital, National Clinical Research Center for Geriatrics Ge, Ning; Sichuan University West China Hospital, National Clinical Research Center for Geriatrics Yue, Jirong; Sichuan University West China Hospital, Department of Geriatrics; Sichuan University West China Hospital, National Clinical Research Center for Geriatrics  Vue, Jirong; Sichuan University West China Hospital, National Clinical Research Center for Geriatrics  Diagnostics  Diagnostics  Epidemiology, Geriatric medicine, Rheumatology	Manuscript ID	bmjopen-2023-078034.R1
Complete List of Authors:  Tu, Xiangping; Sichuan University West China Hospital, Department of Geriatrics; Sichuan University West China Hospital, National Clinical Research Center for Geriatrics Lin, Taiping; Sichuan University West China Hospital, Department of Geriatrics; Sichuan University West China Hospital, National Clinical Research Center for Geriatrics Ju, Yuan; Sichuan University West China Hospital, National Clinical Research Center for Geriatrics Jiang, Tingting; Sichuan University West China Hospital, National Clinical Research Center for Geriatrics Jiang, Tingting; Sichuan University West China Hospital, Department of Geriatrics; Sichuan University West China Hospital, National Clinical Research Center for Geriatrics Ge, Ning; Sichuan University West China Hospital, National Clinical Research Center for Geriatrics Yue, Jirong; Sichuan University West China Hospital, Department of Geriatrics; Sichuan University West China Hospital, National Clinical Research Center for Geriatrics Yue, Jirong; Sichuan University West China Hospital, National Clinical Research Center for Geriatrics  Sichuan University West China Hospital, National Clinical Research Center for Geriatrics Yue, Jirong; Sichuan University West China Hospital, National Clinical Research Center for Geriatrics  Sichuan University West China Hospital, National Clinical Research Center for Geriatrics Yue, Jirong; Sichuan University West China Hospital, National Clinical Research Center for Geriatrics  Secondary Subject Heading:  Diagnostics  Epidemiology, Geriatric medicine, Rheumatology	Article Type:	Original research
Geriatrics; Sichuan University West China Hospital, National Clinical Research Center for Geriatrics Lin, Taiping; Sichuan University West China Hospital, Department of Geriatrics; Sichuan University West China Hospital, National Clinical Research Center for Geriatrics Ju, Yuan; Sichuan University, Sichuan University library Shu, Xiaoyu; Sichuan University West China Hospital, Department of Geriatrics; Sichuan University West China Hospital, National Clinical Research Center for Geriatrics Jiang, Tingting; Sichuan University West China Hospital, Department of Geriatrics; Sichuan University West China Hospital, National Clinical Research Center for Geriatrics Ge, Ning; Sichuan University West China Hospital, Department of Geriatrics; Sichuan University West China Hospital, National Clinical Research Center for Geriatrics Yue, Jirong; Sichuan University West China Hospital, Department of Geriatrics; Sichuan University West China Hospital, National Clinical Research Center for Geriatrics	•	14-Dec-2023
Heading < /b>: Diagnostics  Secondary Subject Heading: Epidemiology, Geriatric medicine, Rheumatology  Phoumatology < INTERNAL MEDICINE GERIATRIC MEDICINE	Complete List of Authors:	Research Center for Geriatrics Lin, Taiping; Sichuan University West China Hospital, Department of Geriatrics; Sichuan University West China Hospital, National Clinical Research Center for Geriatrics Ju, Yuan; Sichuan University, Sichuan University library Shu, Xiaoyu; Sichuan University West China Hospital, Department of Geriatrics; Sichuan University West China Hospital, National Clinical Research Center for Geriatrics Jiang, Tingting; Sichuan University West China Hospital, Department of Geriatrics; Sichuan University West China Hospital, National Clinical Research Center for Geriatrics Ge, Ning; Sichuan University West China Hospital, National Clinical Research Center for Geriatrics Yue, Jirong; Sichuan University West China Hospital, Department of Geriatrics; Sichuan University West China Hospital, Department of Geriatrics; Sichuan University West China Hospital, National Clinical
Phoumatology < INTERNAL MEDICINE CERTATRIC MEDICINE		Diagnostics
Rheumatology < INTERNAL MEDICINE, GERIATRIC MEDICINE,	Secondary Subject Heading:	Epidemiology, Geriatric medicine, Rheumatology
Systematic Review	Keywords:	

SCHOLARONE™ Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1	
2	
2	
2	
4	
5	
6	
7	
,	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
ンソ	

1	Sarcopenia in Systemic Sclerosis: Prevalence and Impact - A Systematic Review and
2	Meta-analysis
3	Xiangping Tu, <sup>1</sup> Taiping Lin, <sup>1</sup> Yuan Ju, <sup>2</sup> Xiaoyu Shu, <sup>1</sup> Tingting Jiang, <sup>1</sup> Ning Ge, <sup>1</sup> Jirong Yue <sup>1*</sup>
4	<sup>1</sup> Department of Geriatrics and National Clinical Research Center for Geriatrics, West China
5	Hospital, Sichuan University, Chengdu Sichuan, China, <sup>2</sup> Sichuan University Library, Chengdu
6	Sichuan, China.
7	Correspondence to: Dr. Jirong Yue, Department of Geriatrics, West China Hospital, Sichuan
8	University, Chengdu Sichuan, 610041, China, <u>yuejirong11@hotmail.com</u> ; Telephone
9	+8618980601143.
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	

#### 1 Abstract

- **Objective** This review aims to provide an estimate of sarcopenia prevalence and its impact
- 3 on clinical characteristics in patients with systemic sclerosis (SSc).
- **Design** Systematic review and meta-analysis.
- 5 Data sources Embase, Medline, Web of Science, and the Cochrane Central Register of
- 6 Controlled Trials were systemically searched from inception to May 24, 2023.
- 7 Eligibility criteria for selecting studies We included observational studies that reported the
- 8 prevalence of sarcopenia in patients with SSc.
- 9 Data extraction and synthesis Two reviewers independently performed study selection and
- data extraction using standardized methods. Risk of bias was assessed using the Agency for
- Healthcare Research and Quality (AHRQ) scale and the Newcastle–Ottawa Scale
- 12 (NOS). Meta-analysis was conducted using random effects models.
- **Results** A total of 4583 articles were screened and 9 studies with data from 815 patients were
- included in the analysis (8 cross-sectional studies and 1 retrospective cohort study). The
- overall prevalence of sarcopenia in SSc patients was 22% (95% CI 17% to 28%). SSc
- patients with sarcopenia had a poorer quality of life (MD -12.02; 95% CI -19.11 to -4.93) and
- 17 higher CRP levels (SMD 0.67 mg/L; 95% CI 0.35 to 1.00).
- 18 Conclusions Sarcopenia is common in patients with SSc. SSc patients with sarcopenia had a
- worse quality of life and higher CRP levels, based on our findings. Given the detrimental
- 20 impact of sarcopenia on quality of life, future efforts aimed at early identification of sarcopenia
- in the clinical assessment of patients with SSc may have significance.
- 22 PROSPERO registration number CRD42022368326

# 2 Strengths and limitations of this study

- 3 This is the first systematic review and meta-analysis to evaluate the prevalence and impact of
- 4 sarcopenia in patients with systemic sclerosis.
- 5 We conducted a comprehensive literature search to ensure that all eligible studies were
- 6 included in the analysis.
- 7 We could not establish a definitive causal relationship between sarcopenia and systemic
- 8 sclerosis.
- 9 Even though this review included studies from different continents (Europe, South America,
- and Asia), data on participant race were not accessible, limiting its potential applicability to
- 11 specific patient subgroups.

#### Introduction

Systemic sclerosis (SSc) is a rare immune-mediated rheumatic disease that is characterized by inflammation, microvascular damage, and progressive fibrosis of both the skin and internal organs, such as the gastrointestinal tract, lung, heart, and kidney.[1,2] Depending on the extent of cutaneous involvement, SSc can be classified as limited cutaneous SSc (lcSSc) or diffuse cutaneous SSc (dcSSc).[3] Patients with SSc are at risk for body composition abnormalities, including loss of skeletal muscle mass, due to malnutrition resulting from gastrointestinal involvement, chronic inflammation, and steroid therapy. [4–7] In addition, heart, lung, and joint involvement in SSc patients can lead to impaired exercise ability and decreased physical activity.[8] These factors are closely related to sarcopenia, which is an age-related disease characterized by progressive and generalized loss of skeletal muscle mass and strength.[9] The coexistence of sarcopenia and SSc can exacerbate the patient's health issues and increase their healthcare costs, posing significant challenges for healthcare professionals. According to a meta-analysis, the prevalence of sarcopenia in community-dwelling elders aged over 60 years was 11% (95% CI: 8 to 13%) in men and 9% (95% CI: 7 to 11%) in women.[10] The presence of sarcopenia increases the risk of falling, functional decline, frailty, and mortality, leading to poor quality of life and significant healthcare expenses.[11] The high prevalence of sarcopenia in older adults, combined with its detrimental consequences, warrants the need for effective prevention and management strategies. In SSc patients, addressing sarcopenia may improve their functional status and overall health outcomes, highlighting the importance of early screening and intervention. Healthcare professionals need to recognize the interplay between SSc and sarcopenia to provide optimal care for these patients.

In recent years, the presence of sarcopenia in SSc has garnered attention in several studies.[4– 7,12–16] The documented prevalence of sarcopenia in SSc varies widely from 10.7% to 42% among different studies, which can be attributed to several factors.[4,5] Differences in diagnostic criteria and assessment methods utilized in various studies, such as those proposed by the European Working Group of Sarcopenia in Older People (EWGSOP)[9,17] and the Asian Working Group for Sarcopenia (AWGS),[18] can result in variations in the evaluation of muscle mass in patients. Furthermore, the influence of sarcopenia on the clinical features of SSc patients has been a topic of debate. For instance, Caimmi et al.[12] suggested that individuals with SSc and sarcopenia had a longer duration of disease; the longer disease duration means that patients live longer with the disease, while Siegert et al.[6] contradicted this claim and found no difference between sarcopenia and disease duration in SSc patients. Currently, no comprehensive systematic review or meta-analysis has examined sarcopenia in SSc. Therefore, we conducted a systematic review and meta-analysis to identify the diagnostic criteria for sarcopenia and evaluate the most reliable evidence on the prevalence of sarcopenia in SSc patients, as well as the effect of sarcopenia on the clinical features of SSc patients.

#### Methods

# Data sources and search strategy

This systematic review and meta-analysis was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guideline[19] and registered in PROSPERO (CRD42022368326). We systemically searched four electronic databases, including Embase, Medline, Web of Science, and the Cochrane Central Register of Controlled Trials, to identify all relevant articles relating to sarcopenia and SSc, without language

- 1 restrictions. Our search encompassed all records published from inception to May 24, 2023,
- 2 utilizing the following terms: 'systemic sclerosis', 'scleroderm\*', 'SSc', 'muscular atrophy',
- 3 'sarcopen\*' and 'myopen\*' (Supporting Information, Table S1-4). Additionally, we conducted
- 4 a manual search of the reference lists of the included articles to identify potential studies that
- 5 may have been overlooked by the principal search.

#### Inclusion and exclusion criteria

- 7 The following inclusion and exclusion criteria were employed for this systematic review and
- 8 meta-analysis: (1) studies conducted exclusively on adult patients (age >18 years) diagnosed
- 9 with SSc; (2) studies reporting the prevalence of sarcopenia in SSc patients; (3) studies defining
- sarcopenia as low muscle mass (LMM) plus low muscle strength (LMS), and/or low physical
- 11 performance (LPP), or LMM alone; LMM was evaluated by dividing appendicular skeletal
- muscle mass (in kilograms) by height in meters squared, LMS by hand grip strength, LPP by
- gait speed or short physical performance battery, and diagnostic cutoffs varied depending on
- the criterion[9,17,18,20]; (4) studies measuring lean mass or muscle mass using one of the four
- main techniques: dual-energy X-ray absorptiometry (DXA), bioelectrical impedance analysis
- 16 (BIA), magnetic resonance imaging (MRI) and computed tomography (CT); and (5)
- observational studies. Conversely, the exclusion criteria were as follows: repeated studies
- 18 (defined as either identical data or identical articles).

# Outcomes

- 20 The main outcomes of this systematic review comprise two aspects: firstly, the prevalence of
- 21 sarcopenia among patients with SSc, and secondly, the clinical features of patients with SSc
- 22 who suffer from sarcopenia compared to those who do not. These clinical features

2 the Short Form-36 (SF-36) survey[21], the pulmonary function (the forced vital capacity (FVC)

predicted value), and the C-relative protein level. These features are frequently the focus of

clinical studies in patients with SSc, and it is of significant interest to understand how

sarcopenia impacts them.

## Study selection and data extraction

- 7 After removing duplicates, the studies identified through the search strategy underwent
- 8 eligibility assessment by two reviewers (X.T. and T.L.), who independently screened the titles
- 9 and abstracts and assigned them to one of three categories: 'include,' 'exclude,' or 'maybe.'
- 10 Subsequently, the full-text articles of those categorized as 'include' or 'maybe' were reviewed
- to arrive at a final selection, with any discrepancies between the reviewers resolved by a third
- reviewer (J.Y.). Two reviewers (X.T. and X.S.) independently extracted the following variables
- using a pre-defined data collection form: first author, publication year, country, study design,
- sample size, mean age, number of females, disease subtype, mean disease duration, SSc
- diagnostic criteria, sarcopenia diagnostic criteria, assessment method for detecting sarcopenia,
- and prevalence of sarcopenia. Additionally, we also collected data on clinical features in the
- 17 form of mean ± standard deviation (SD). For those studies that were not expressed as mean
- 18 ± SD, we performed data conversion with the method recommended by Luo et al. [22] and
- 19 Wan et al.[23]

#### Assessment of quality

- 21 Two authors (X.T. and T.J.) independently assessed the quality of the included studies using
- the Agency for Healthcare Research and Quality (AHRQ)[24] scale in cross-sectional studies.

- 1 This tool consists of 11 questions, with a 'no' or 'unclear' receiving 0 points and a 'yes' receiving
- 2 1 point. Low-quality articles received scores of 0–3, moderate-quality scores of 4–7, and high-
- 3 quality scores of 8–11. The Newcastle–Ottawa Scale (NOS) was used to judge the quality of
- 4 the cohort study.[25] The NOS scoring system assigns points from 0 to 9. We assigned values
  - ranging from 0 to 3, 4 to 6, and 7 to 9 for low, moderate, and high-quality, accordingly. Any
- 6 discrepancies were resolved through discussion or consensus with a third author (J.Y.).

# 7 Statistical Analysis

- 8 The prevalence of sarcopenia in SSc patients was determined by calculating the proportion of
- 9 patients with sarcopenia in each study and conducting a meta-analysis of single proportions.
- 10 We performed this meta-analysis using Stata/SE (Version 12.0, StataCorp, Texas, USA).
- Forest plots were used to illustrate the prevalence of sarcopenia, along with corresponding 95%
- 12 confidence intervals (CIs) for each study and the overall estimate. Clinical characteristics such
- as disease duration, the SF-36 value, the FVC predicted value, and the CRP level from studies
- that compared SSc patients with and without sarcopenia were also analyzed using Review
- Manager (Version 5.4, The Cochrane Collaboration, Oxford, UK) and expressed as mean
- difference (MD) or standardized mean difference (SMD) with 95% CI. Heterogeneity across
- studies was assessed via the I<sup>2</sup> statistic, with values of 25% being considered low, 50%
- moderate, and 75% high.[26] Considering the variation in the definition of sarcopenia,
- 19 diagnostic criteria, and population characteristics among the included studies, this study
- 20 employed a random-effects model.
- 21 Subgroup analyses were conducted to investigate potential sources of heterogeneity, focusing
- on sarcopenia definition (1 vs >1 diagnostic criteria), disease subtype, and mean age (< 60 vs

- ≥60 years). The reasons for grouping in subgroup analysis are as follows. Firstly, variability in the definition of sarcopenia will result in varied prevalence estimates for patients with SSc. Unsurprisingly, increasing the number of necessary criteria in a sarcopenia definition will eventually diminish sarcopenia prevalence. Additionally, the disease subtype is an important factor that affects the prevalence of sarcopenia. Patients with dcSSc are more prone to develop sarcopenia.[14] Moreover, age is an essential factor that influences the onset and course of sarcopenia, with the prevalence of sarcopenia increasing with age. Meta-regressions were also conducted on sample size, mean age, percentage of female patients, and duration of SSc. However, due to limited data on the clinical characteristics of SSc patients with and without sarcopenia, subgroup analyses and meta-regressions were not conducted. To evaluate the stability of pooled results, sensitivity analysis was performed by excluding one study at a time.
- 14 Patient and public involvement

0.05 for all analyses.

Patients and/or the public were not involved in the design, conduct, reporting, or dissemination

Publication bias was evaluated using Egger's test[27]. Statistical significance was set at P <

- 16 plans of this research.
- 17 Results

- 18 Search results
- 19 A comprehensive search of databases yielded 4583 articles. After eliminating duplicates (n =
- 20 1523), the remaining 3060 titles and abstracts were screened. Subsequently, 25 relevant articles
- 21 underwent full-text reading, and 16 were excluded for reasons specified in the flow chart and
- Table S5 in the supplement. Ultimately, 9 studies were eligible for inclusion in this meta-

- 1 analysis (Figure 1).
- 2 Study characteristics
- 3 Table S6 provides an overview of the characteristics of the studies included in this meta-
- 4 analysis. A total of 815 SSc patients from 9 eligible studies[4–7,12–16] published between
  - 2018 and 2022 were included. The mean age of the patients ranged from 52.5 to 64.1 years,
- 6 while the mean duration of SSc ranged from 6 to 12.8 years. The majority of the studies (8 out
- of 9) had a cross-sectional design,[4–6,12–16] with one being a retrospective cohort study.[7]
- 8 The studies were conducted in various regions, with five from Europe,[5–7,12,16] two from
- 9 South America,[13,15], and two from Asia.[4,14]
- 10 Risk of bias
- 11 According to the AHRQ and NOS ratings, 8 of the eligible studies[4–7,12,14–16] were of
- moderate quality, with only one article[13] classified as high quality. (Table S7-8 in the
- 13 supplement).
- 14 Methods used to assess sarcopenia
- Table S6 provides an overview of the diagnostic criteria used to evaluate sarcopenia across the
- included studies. Among them, seven studies[4–7,13,15,16] employed EWGSOP criteria (5
- 17 EWGSOP2010 and 2 EWGSOP2019) while one [14] used AWGS criteria. Three studies [5,7,12]
- solely relied on LMM for sarcopenia diagnosis, while six studies[4,6,13–16] utilized LMM
- 19 combined with LMS and/or LPP. The sarcopenia diagnostic criteria and cutoff values in the
- studies are summarized in Table 1. Muscle mass was measured using dual-energy X-ray
- 21 absorptiometry in seven studies[5,7,12–16] and bioelectrical impedance analysis in two
- 22 studies[4,6]. Handgrip dynamometry was utilized to assess muscle strength in six

- 2 battery (SPPB) (two studies[13,16]) were used to evaluate physical performance.
- 3 Sarcopenia prevalence

- 4 Overall sarcopenia prevalence
- 5 The nine studies included in this review reported the prevalence of sarcopenia in SSc patients,
- 6 ranging from 10.7% to 42% (Table S6). The pooled prevalence of sarcopenia in patients with
- 7 SSc was estimated at 22% (95% CI 17% to 28%), as shown in Figure 2.
- 8 Subgroup analysis of sarcopenia prevalence
- 9 The prevalence of sarcopenia differed in studies that utilized a single criterion [LMM; 28% (95%
- 10 CI 16% to 42%)] versus those that employed >1 criterion [LMM + LMS and/or LPP; 20%
- (95% CI 15% to 25%)], with no statistically significant difference noted (P = 0.234, Figure S1
- in the supplement). Subgroup analysis based on disease subtype revealed that sarcopenia
- prevalence in dcSSc [30% (95% CI 23% to 37%)] was higher than that in lcSSc [23% (95% CI
- 14 12% to 36%)], and the difference was not statistically significant (P = 0.339, Figure S2 in the
- supplement). The United Nations defines an older person as someone above the age of 60.
- Therefore, we also performed a subgroup analysis stratified by the mean age of the participants,
- with < 60 and  $\ge 60$  years as the cutoff points. The prevalence of sarcopenia was lower in
- patients younger than 60 years [20% (95% CI 12% to 29%)] vs those older than 60 years [24%]
- (95% CI 17% to 32%)], but the difference was not of statistical significance (P = 0.539, Figure
- 20 S3 in the supplement).
- 21 Meta-regression analyses
- 22 The results of the meta-regression analyses indicated that there was no significant association

- between the prevalence of sarcopenia and sample size (P = 0.424), mean age of patients (P =
- 2 0.532), the proportion of female patients (P = 0.449), or duration of SSc (P = 0.255). These
- 3 findings are summarized in Table S9 of the supplementary material.
- 4 Impact of sarcopenia on the clinical characteristics of SSc patients
- 5 Duration of SSc
- 6 Data from a total of four studies comprising 511 patients were included in the meta-analysis of
- 7 SSc duration, which revealed that individuals with sarcopenia did not have a longer disease
- 8 duration than those without sarcopenia [MD 2.97 years (95% CI -0.13 to 6.08);  $I^2 = 90\%$ ,
- 9 Figure 3A].
- 10 Quality of life
- 11 The meta-analysis included two studies with a total of 191 patients, which provided data on the
- 12 SF-36 value. The findings of the meta-analysis indicated that patients with sarcopenia had a
- lower SF-36 value compared to those without sarcopenia [MD -12.02 (95% CI -19.11 to -4.93);
- $I^2 = 71\%$ , Figure 3B], that is, having sarcopenia was associated with poorer quality of life
- 15 compared with those without sarcopenia.
- 16 Pulmonary function
- 17 The meta-analysis incorporated two studies involving a total of 320 patients that reported data
- on the FVC predicted value. The results indicated that patients with sarcopenia did not have a
- lower FVC predicted value than those without sarcopenia [MD -4.02% (95% CI -8.67 to 0.62);
- $I^2 = 0\%$ , Figure 3C]. Therefore, there was no significant difference in pulmonary function
- 21 between sarcopenia and non-sarcopenia patients.
- 22 CRP level

- 2 between sarcopenia and CRP level. The results showed that sarcopenia was associated with a
- 3 higher CRP level than no sarcopenia [SMD 0.67 mg/L (95% CI 0.35 to 1.00);  $I^2 = 0\%$ , Figure
- 4 3D].

# 5 Sensitivity and publication bias analysis

- 6 The sensitivity analysis revealed that the overall prevalence of sarcopenia was not significantly
- 7 affected by any individual study (Figure S4 in the supplementary material). In addition, Egger's
- 8 test suggested no publication bias in this review (P = 0.311, Figure S5 in the supplement).

#### 9 Discussion

# 10 Primary results

- 11 In this meta-analysis encompassing nine studies, the pooled prevalence of sarcopenia among
- 12 815 patients diagnosed with systemic sclerosis (SSc) was estimated to be 22%, which was
- significantly greater than that in community-dwelling older adults.[28] Notably, SSc patients
- 14 diagnosed with sarcopenia had poorer quality of life and a higher CRP level, while no
- significant difference was noted for disease duration and FVC predicted value when compared
- 16 to patients without sarcopenia.

#### 17 Mechanism basis

- 18 Sarcopenia, a condition characterized by loss of muscle mass and function, can be age-
- 19 associated (primary sarcopenia) or secondary to chronic diseases, including malignant tumors
- and musculoskeletal diseases.[29–31] Compared with other chronic inflammatory rheumatic
- 21 diseases, sarcopenia has not been extensively evaluated in SSc. Recently, some studies have
- focused on the presence of sarcopenia in SSc. Nevertheless, the pathogenesis of sarcopenia in

 SSc remains unclear. Possible mechanisms contributing to the development of sarcopenia in SSc include (1) malnutrition: gastrointestinal involvement is the most frequent internal complication of SSc[32]. Symptoms such as esophageal reflux, early satiety, nausea, and vomiting may lead to reduced caloric intake. [12] Additionally, fibrosis of the bowel wall and small intestine bacterial overgrowth can result in malabsorption of nutrients. Therefore, malnutrition is prevalent in SSc patients. One study in community-dwelling older adults demonstrated that malnutrition is an independent predictor of sarcopenia (OR: 2.42; 95% CI 1.04 to 5.60)[33]. (2) Oxidative stress and chronic inflammation: oxidative stress, which is an imbalance in oxidant and antioxidant levels, is commonly observed in SSc patients[34]. Increased oxidative stress disrupts the balance between the degradation and resynthesis of skeletal muscle proteins[35]. In addition, chronic low-grade inflammation is detrimental to skeletal muscle in humans[36]. Inflammatory cytokines, such as tumor necrosis factor-α and interleukin-6, have been reported to contribute to the pathogenesis of SSc[37]. These cytokines stimulate protein catabolism and suppress muscle synthesis, ultimately leading to muscle wasting[38]. (3) Physical inactivity: due to pain and joint involvement, physical inactivity is common in SSc patients[39], leading to faster and greater muscle loss[11]. However, the mechanism of sarcopenia in SSc patients remains to be confirmed by future research.

### Interpretation of the results

This review offers unique insight into sarcopenia in patients with SSc. It describes the prevalence of sarcopenia in SSc patients and how it is impacted by the different definitions of sarcopenia. The varying prevalence of sarcopenia may be explained in part by the variety of definitions. However, there was no statistical difference between 1 and >1 diagnostic criteria.

 This might be due to the lack of robustness of the combined results as a result of the small number of studies using one diagnostic criterion. In addition, discrepancies in sarcopenia diagnostic cutoffs among the included studies may have resulted in differing sarcopenia prevalence. Furthermore, our meta-analysis indicated no statistically significant variation in the prevalence of sarcopenia between disease subtypes, which is consistent with the results of Sangaroon et al.[14] It is important to note that this conclusion needs to be interpreted with caution due to the limited number of studies that could be included in the analysis. Although sarcopenia commonly occurs as an age-related process in older individuals[11], it becomes more common as people get older. Our meta-analysis demonstrated that the difference in the prevalence of sarcopenia was not statistically significant between the patients over 60 years old and the patients under 60 years old. Furthermore, patients younger than 60 years old all used >1 criterion to diagnose sarcopenia, which makes the prevalence of sarcopenia in young people even lower. This suggests that, despite the influence of age on the presence of sarcopenia, the illness itself is responsible for sarcopenia onset and progression in SSc patients. Therefore, rheumatologists should screen for sarcopenia even in young SSc patients. However, this conclusion must be confirmed by a large number of high-quality clinical studies. Our meta-analysis also revealed that SSc patients diagnosed with sarcopenia had a poorer quality of life. On the one hand, involvement of the heart, lungs, and joints in SSc patients might result in diminished exercise capacity and decreased physical activity,[8] making SSc patients vulnerable to sarcopenia. On the other hand, sarcopenia is associated with a variety of negative outcomes, including hospitalization, functional decline, falls, and death.[40,41] Therefore, it should come as no surprise that SSc patients with sarcopenia have a higher risk

 of having a worse quality of life. Furthermore, individuals with SSc who had sarcopenia had higher CRP levels, according to our findings. This result is not surprising given that chronic inflammation is a known contributor to secondary sarcopenia.[42] However, our review indicated that no significant difference was noted for disease duration or FVC predicted value between SSc patients with and without sarcopenia. According to the results of Caimmi et al,[12] the longer the disease duration, the greater the risk of sarcopenia. This might be due to the minimal number of studies that could extract data, resulting in false negatives in the pooled study results. Therefore, large prospective cohort studies are required to confirm this conclusion.

### Clinical implications

This meta-analysis provides a comprehensive evaluation of the prevalence, diagnostic criteria, and impact of sarcopenia in SSc patients, which has not been previously done. The results of this study provide an up-to-date estimation of the prevalence of sarcopenia, which can guide sample size calculations for future research. While sarcopenia has been relatively under-studied in SSc compared to other rheumatic diseases, our findings suggested that neither sarcopenia definition, disease subtype nor age affects the prevalence of sarcopenia. SSc patients with sarcopenia had a poorer quality of life, according to our findings. Therefore, early identification and intervention of sarcopenic patients by clinicians is crucial. The high prevalence of sarcopenia in SSc patients highlights the importance of early screening and management. Standardized criteria for sarcopenia diagnosis are also essential in SSc patients to minimize variations in prevalence. These findings have important implications for future research, clinical practice, and policy development in managing sarcopenia in SSc patients, and can

1 potentially improve outcomes for these patients.

## Strengths and weaknesses

- 3 This systematic review undertook a comprehensive and meticulous literature search to ensure
- 4 that all pertinent studies were included in the analysis. The selection of studies, data extraction,
  - and quality assessments were carried out independently by two reviewers, thereby enhancing
- 6 the accuracy and reliability of the results. Subgroup analyses and meta-regression analyses
- 7 were also conducted to explore the possible sources of heterogeneity, while sensitivity and
- 8 publication bias analyses were performed to ensure robust and dependable conclusions.
- 9 Nevertheless, we must acknowledge certain limitations of our study. Firstly, since most of the
- 10 included studies were cross-sectional, it is impossible to establish a definitive causal
- 11 relationship between sarcopenia and SSc. Nonetheless, this is a limitation inherent to the
- original literature and beyond our control. We, therefore, look forward to high-quality
- prospective cohort studies to provide more conclusive evidence on this matter. Secondly, there
- was some heterogeneity among the included studies in terms of factors such as the definition
- of sarcopenia, measurement approaches, and diagnostic cut-offs. Moreover, most of the studies
- had small sample sizes. Therefore, future studies should aim to use uniform diagnostic criteria
- 17 for sarcopenia and expand the sample size to improve the quality of research. Finally, even
- though this review included studies from different continents (Europe, South America, and
- Asia), data on participant race were not accessible, limiting its potential applicability to specific
- 20 patient subgroups.

### Conclusions

22 Sarcopenia is common in patients with SSc. SSc patients with sarcopenia had a worse quality

- 1 of life and higher CRP levels, based on our findings. Given the detrimental impact of
- 2 sarcopenia on quality of life, future efforts aimed at early identification of sarcopenia in the
- 3 clinical assessment of patients with SSc may have significance.

### 4 Contributors

- 5 All authors conceived and designed this review; YJ, XPT, and JRY developed the search
- 6 strategy; XPT and TPL screened studies; XPT and XYS extracted data; XPT and TTJ appraised
- 7 study quality; XPT and NG conducted data analysis; XPT drafted the manuscript; all authors
- 8 revised the manuscript for important intellectual content. JRY had full access to all the data in
- 9 the study and took responsibility for the integrity of the data and the accuracy of the data
- 10 analysis.

## 11 Funding

- 12 This study was supported by grants from the Chinese National Science & Technology Pillar
- 13 Program (2020YFC2005600), Sichuan Science and Technology Program (2021YFS0136)
- 14 1·3·5 projects for disciplines of excellence–Clinical Research Incubation Project, West China
- Hospital, Sichuan University (19HXFH012), National Clinical Research Center for Geriatrics,
- West China Hospital, Sichuan University (Z20192009) 1.3.5 project for disciplines of
- excellence, West China Hospital, Sichuan University (ZYJC21005).

### 18 Role of the Funder:

- 19 The funder of the study had no role in study design, data collection, data analysis, data
- 20 interpretation, or writing of the report.

### 21 Competing interests

None declared.

2 Not required.

- 3 Ethics approval
- 4 Not applicable.
- 5 Data availability statement
- 6 The data are accessible upon reasonable request from the corresponding author.
- 7 Online supplementary material
- 8 Additional supporting information may be found online in the Supporting Information section
- 9 at the end of the article.

### Reference

- 2 1 Denton CP, Khanna D. Systemic sclerosis. *The Lancet*. 2017;390:1685–99.
- 3 2 Zhong L, Pope M, Shen Y, et al. Prevalence and incidence of systemic sclerosis: A
- 4 systematic review and meta-analysis. International Journal of Rheumatic Diseases.
- 5 2019;22:2096–107.
  - 3 LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification,
  - subsets and pathogenesis. *J Rheumatol*. 1988;15:202–5.
- 8 4 Sari A, Esme M, Aycicek GS, et al. Evaluating skeletal muscle mass with ultrasound in
- patients with systemic sclerosis. *Nutrition*. 2021;84:110999.
- 5 Corallo C, Fioravanti A, Tenti S, et al. Sarcopenia in systemic sclerosis: the impact of
- nutritional, clinical, and laboratory features. *Rheumatol Int*. 2019;39:1767–75.
- 12 6 Siegert E, March C, Otten L, et al. Prevalence of sarcopenia in systemic sclerosis: assessing
- body composition and functional disability in patients with systemic sclerosis. *Nutrition*.
- 14 2018;55–56:51–5.
- 7 Paolino S, Goegan F, Cimmino MA, et al. Advanced microvascular damage associated
- with occurrence of sarcopenia in systemic sclerosis patients: Results from a retrospective
- 17 cohort study. *Clinical and Experimental Rheumatology*. 2020;38 Suppl 125(3):65-72.
- 8 Cuomo G, Santoriello C, Polverino F, et al. Impaired exercise performance in systemic
- 19 sclerosis and its clinical correlations. Scandinavian Journal of Rheumatology.
- 20 2010;39:330–5.
- 9 Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on
- definition and diagnosis: Report of the European Working Group on Sarcopenia in Older
- 23 People. *Age Ageing*. 2010;39:412–23.
- 24 10 Papadopoulou SK, Tsintavis P, Potsaki G, et al. Differences in the Prevalence of
- 25 Sarcopenia in Community-Dwelling, Nursing Home and Hospitalized Individuals. A
- Systematic Review and Meta-Analysis. *J Nutr Health Aging*. 2020;24:83–90.
- 27 11 Cruz-Jentoft AJ, Sayer AA. Sarcopenia. *The Lancet*. 2019;393:2636–46.
- 28 12 Caimmi C, Caramaschi P, Venturini A, et al. Malnutrition and sarcopenia in a large cohort
- of patients with systemic sclerosis. *Clin Rheumatol*. 2018;37:987–97.
- 30 13 Hax V, do Espírito Santo RC, Dos Santos LP, et al. Practical screening tools for sarcopenia
- in patients with systemic sclerosis. *PLoS ONE*. 2021;16(1):e0245683.
- 32 14 Sangaroon A, Foocharoen C, Theerakulpisut D, et al. Prevalence and clinical association
- of sarcopenia among Thai patients with systemic sclerosis. *Sci Rep.* 2022;12:18198.

- 15 Rincón IDR, Alak M, Alsina G, et al. Sarcopenia in systemic sclerosis. Arthritis and Rheumatology. 2019;71(S10):2957–8.
- 16 Efremova AO, Toroptsova NV, Nikitinskaya OA, et al. The frequency of sarcopenia and factors associated with muscle mass in women with systemic scleroderma (Pilot Study).
- Osteoporosis International. 2022;32(S1):S409.
- 17 Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48:16–31.
- 18 Chen LK, Liu LK, Woo J, et al. Sarcopenia in Asia: consensus report of the Asian Working
- Sarcopenia. J AmMed Dir Assoc. 2014;15(2):95-101. for
- 10.1016/j.jamda.2013.11.025

- 19 Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
- 20 Chen LK, Woo J, Assantachai P, et al. Asian Working Group for Sarcopenia: 2019
- Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc.
- 2020;21:300-307.e2.
- 21 Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Medical care*. 1992;30(6):473-83.
- 22 Luo D, Wan X, Liu J, et al. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2018;27:1785–805.
- 23 Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard deviation from the
- sample size, median, range and/or interquartile range. BMC Med Res Methodol.
- 2014;14:135.
- 24 Zeng X, Zhang Y, Kwong JSW, et al. The methodological quality assessment tools for
- preclinical and clinical studies, systematic review and meta-analysis, and clinical practice
- guideline: a systematic review. J Evid Based Med. 2015;8:2–10.
- 25 Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality
- of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–5.
- 26 Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses.
- BMJ. 2003;327:557-60.
- 27 Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple,
- graphical test. BMJ. 1997;315:629–34.
- 28 Simsek H, Meseri R, Sahin S, et al. Prevalence of sarcopenia and related factors in
- community-dwelling elderly individuals. Saudi Med J. 2019;40:568–74.

- 2 Neuroblastoma. *Journal of Surgical Research*. 2019;236:101–5.
- 3 30 Matsunaga T, Miyata H, Sugimura K, et al. Prognostic Significance of Sarcopenia and
- 4 Systemic Inflammatory Response in Patients With Esophageal Cancer. *Anticancer Res.*
- 5 2019;39:449–58.
- 6 31 Laurent MR, Dedeyne L, Dupont J, *et al.* Age-related bone loss and sarcopenia in men. *Maturitas*. 2019;122:51–6.
- 8 32 Clements PJ, Becvar R, Drosos AA, *et al.* Assessment of gastrointestinal involvement. *Clin Exp Rheumatol.* 2003;21(3 Suppl 29):S15-8.
- 10 33 Kurose S, Nishikawa S, Nagaoka T, et al. Prevalence and risk factors of sarcopenia in
- community-dwelling older adults visiting regional medical institutions from the Kadoma
- Sarcopenia Study. *Sci Rep.* 2020;10:19129. doi: 10.1038/s41598-020-76185-0
- 13 34 Doridot L, Jeljeli M, Chêne C, et al. Implication of oxidative stress in the pathogenesis of
- systemic sclerosis via inflammation, autoimmunity and fibrosis. *Redox Biology*.
- 15 2019;25:101122.
- 35 Meng SJ, Yu LJ. Oxidative Stress, Molecular Inflammation and Sarcopenia. *International Journal of Molecular Sciences*. 2010;11:1509–26. doi: 10.3390/ijms11041509
- 18 36 Howard C, Ferrucci L, Sun K, et al. Oxidative protein damage is associated with poor grip
- strength among older women living in the community. *Journal of Applied Physiology*.
- 20 2007;103:17–20.
- 37 Shima Y. Cytokines Involved in the Pathogenesis of SSc and Problems in the Development
   of Anti-Cytokine Therapy. *Cells*. 2021;10:1104.
- 23 38 Bano G, Trevisan C, Carraro S, *et al.* Inflammation and sarcopenia: A systematic review and meta-analysis. *Maturitas*. 2017;96:10–5.
- 25 39 Liem SIE, Meessen JMTA, Wolterbeek R, *et al.* Physical activity in patients with systemic sclerosis. *Rheumatol Int.* 2018;38:443–53.
- 40 Tsekoura M, Kastrinis A, Katsoulaki M, *et al.* Sarcopenia and Its Impact on Quality of
   Life. *Adv Exp Med Biol.* 2017;987:213–8.
- 41 Beaudart C, Rizzoli R, Bruyère O, *et al.* Sarcopenia: burden and challenges for public health. *Arch Public Health*. 2014;72:45.
- 42 Wang C, Bai L. Sarcopenia in the elderly: basic and clinical issues. *Geriatr Gerontol Int*.
   2012;12:388–96.
- 33 43 Baumgartner RN, Koehler KM, Gallagher D, et al. Epidemiology of sarcopenia among the

- 44 Fried LP, Tangen CM, Walston J, *et al.* Frailty in older adults: evidence for a phenotype. *J Gerontol A Biol Sci Med Sci.* 2001;56:M146-156.
- 4 45 Lauretani F, Russo CR, Bandinelli S, *et al.* Age-associated changes in skeletal muscles and their effect on mobility: an operational diagnosis of sarcopenia. *J Appl Physiol* (1985). 2003;95:1851–60.
- 46 Gould H, Brennan SL, Kotowicz MA, *et al.* Total and appendicular lean mass reference ranges for Australian men and women: the Geelong osteoporosis study. *Calcif Tissue Int.* 2014;94:363–72.
- 47 Dodds RM, Syddall HE, Cooper R, *et al.* Grip strength across the life course: normative
   data from twelve British studies. *PLoS One*. 2014;9:e113637.
- 48 Pavasini R, Guralnik J, Brown JC, *et al.* Short Physical Performance Battery and all-cause
   mortality: systematic review and meta-analysis. *BMC Med.* 2016;14:215.
- 49 Cesari M, Kritchevsky SB, Newman AB, *et al.* Added value of physical performance measures in predicting adverse health-related events: results from the Health, Aging And
   Body Composition Study. *J Am Geriatr Soc.* 2009;57:251–9.
- 50 Studenski S, Perera S, Patel K, *et al.* Gait speed and survival in older adults. *JAMA*. 2011;305:50–8.

Table 1 Criteria and cutoff points used to detect sarcopenia in each study

First author and	Sarcopenia	Cutoff points
year	diagnostic criteria	Cuton points
Caimmi (2018)[12]	SMI	LMM: ASM/height2 < 7.26 kg/m <sup>2</sup> for men
		and < 5.50 kg/m <sup>2</sup> for women.[43]
Siegert (2018)[6]	EWGSOP (2010)	LMM: ALM/height2 < 7.26 kg/m2 for men
		and <5.50 kg/m2 for women.[43]
	9	LMS: BMI ≤ 24, HGS ≤ 29 kg; 24.1 ≤ BMI ≤ 26, HGS ≤ 30 kg; 26.1 ≤ BMI ≤ 28, HGS ≤
	10	30 kg; BMI > 28, HGS ≤ 32 kg for men.
		$BMI \le 23$ , $HGS \le 17$ kg; $23.1 \le BMI \le 26$ , $HGS \le 17.3$ kg; $26.1 \le BMI \le 29$ , $HGS \le 18$
		kg; BMI > 29, HGS ≤ 21 kg for
		women.[44]
Corallo (2019)[5]	EWGSOP (2010)	LMM: RSMI < 7.26 kg/m2 for men and < 5.50
( /L ]		kg/m2 for women.[43]
Rincon (2019)[15]	EWGSOP (2010)	LMM: RSMI < 7.26 kg/m2 for men and < 5.50
(2019)[10]		kg/m2 for women.[43]
		LMS: HGS< 30 kg for men and< 20 kg for
		women.[45]
		LPP: GS< 0.8 m/s (both genders).[45]
Paolino (2020 )	EWGSOP (2010)	LMM: RSMI < 7.26 kg/m2 for men and < 5.50
[7]		kg/m2 for women.[43]
Hax (2021)	EWGSOP (2019)	LMM: ASMI < 7.0 kg/m <sup>2</sup> for men and < 5.5
		kg/m² for women.[46]
		LMS: HGS < 27 kg for men and < 16 kg for
		women.[47] LPP: SPPB ≤ 8 point score.[48]

	I	
First author and	Sarcopenia	Cutoff points
year	diagnostic criteria	
Sari (2021)[4]	EWGSOP (2010)	LMM: ASMI < 7.26 kg/m2 for men and <5.50
		kg/m2 for women.[43] LMS: BMI ≤ 24, HGS ≤ 29 kg; 24.1 ≤ BMI ≤ 26, HGS ≤ 30 kg; 26.1 ≤ BMI ≤ 28, HGS ≤
		30 kg; BMI > 28, HGS ≤ 32 kg for men.
		$BMI \le 23, HGS \le 17 \text{ kg}; 23.1 \le BMI \le 26, \\ HGS \le 17.3 \text{ kg}; 26.1 \le BMI \le 29, HGS \le 18$
		kg; BMI $>$ 29, HGS $\leq$ 21 kg for
	$O_{\lambda}$	women.[44]
Efremova (2022)[16]	EWGSOP (2019)	LMM: ASMI < 7.0 kg/m <sup>2</sup> for men and < 5.5
		kg/m <sup>2</sup> for women.[46]
		LMS: HGS < 27 kg for men and < 16 kg for
		women.[47] or Chair stand > 15 s for
		five rises.[49] LPP: GS $\leq$ 0.8 m/s.[50] or SPPB $\leq$ 8 point score.[48]
Sangaroon (2022)[14]	AWGS (2019)	LMM: ASMI < 7.0 kg/m <sup>2</sup> for men and < 5.4
(===)[1 .]		kg/m² for women.[20]
		LMS: HGS < 28 kg for men and < 18 kg for
		women.[20]
		LPP: GS< 1 m/s (both genders).[20]

SMI, Skeletal Muscle Mass Index; ASM, appendicular skeletal muscle mass; ALM, appendicular lean mass; RSMI, Relative Skeletal Muscle Mass Index; ASMI, Appendicular Skeleton Muscle Index; SPPB, Short Physical Performance Battery; GS, gait speed.

### Figure legend

- 1. Figure 1 The flow chart of the literature selection
- 2. Figure 2 The pooled prevalence of sarcopenia in SSc patients
- 3. Figure 3 Impact of sarcopenia on clinical characteristics in patients with SSc



Figure 1 The flow chart of the literature selection  $146x170mm (300 \times 300 DPI)$ 




Figure 2 The pooled prevalence of sarcopenia in SSc patients  $146 \times 107 \text{mm} (300 \times 300 \text{ DPI})$ 

	Sarcopenia				enia No sarcopenia			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Caimmi 2018	16	8	29	12	7	111	22.1%	4.00 [0.81, 7.19]	
Corallo 2019	11.86	2.52	26	6	1.42	36	27.9%	5.86 [4.79, 6.93]	-
Sangaroon 2022	6.64	5.17	41	6.11	5.31	139	26.3%	0.53 [-1.28, 2.34]	-
Siegert 2018	9.45	6.42	29	8.12	6.8	100	23.7%	1.33 [-1.36, 4.02]	<del></del>
Total (95% CI)			125			386	100.0%	2.97 [-0.13, 6.08]	
Heterogeneity: Tau2:	= 8.69; C	hi² = 2	9.30, d	f= 3 (P	< 0.000	001); [2:	= 90%		-10 -5 0 5 10
Test for overall effect	Z = 1.88	(P = (	0.06)						Favours [Sarcopenia] Favours [No sarcopenia]

#### B Effect of sarcopenia on quality of life (SF-36 value) in SSc patients

	Sa	rcopeni	a	No s	arcope	nia		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Corallo 2019	35.74	3.53	26	50.57	4.73	36	62.4%	-14.83 [-16.89, -12.77]	-
Siegert 2018	40.9	18.53	29	48.26	17.61	100	37.6%	-7.36 [-14.94, 0.22]	-
Total (95% CI)			55			136	100.0%	-12.02 [-19.11, -4.93]	
Heterogeneity: Tau <sup>2</sup> = 19.88; Chi <sup>2</sup> = 3.48, df = 1 (P = 0.06); i <sup>2</sup> = 71% Tool for everall effect, 7 = 2.32 (P = 0.000)									-10 -5 0 5 10
Test for overall effect: Z = 3.32 (P = 0.0009)									Favours [Sarcopenia] Favours [No sarcopenia]

### C Effect of sarcopenia on pulmonary fuction (FVC predicted value) in SSc patients

	Sarcopenia No sarcopenia				Mean Difference	Mean Difference			
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Caimmi 2018	99	26	29	104	23	111	20.0%	-5.00 [-15.39, 5.39]	
Sangaroon 2022	65.85	14.89	41	69.63	15.03	139	80.0%	-3.78 [-8.98, 1.42]	-
Total (95% CI)			70			250	100.0%	-4.02 [-8.67, 0.62]	•
Heterogeneity: $Chi^2 = 0.04$ , $df = 1$ (P = 0.84); $I^2 = 0\%$									-20 -10 0 10 20
Test for overall effect:	Z = 1.70	(P = 0.	09)					Favours [Sarcopenia] Favours [No sarcopenia]	

### D Effect of sarcopenia on CRP in SSc patients



Figure 3 Impact of sarcopenia on clinical characteristics in patients with SSc  $146 \times 136 \text{mm}$  (300 x 300 DPI)

# Sarcopenia in Systemic Sclerosis: Prevalence and Impact - A Systematic Review

### and Meta-analysis

- 1. Table S1 Search strategy by Medline via Ovid SP
- 2. Table S2 Search strategy by Embase via Ovid SP
- 3. Table S3 Search strategy by Web of Science
- Table S4 Search strategy by Cochrane Central Register of Controlled Trials via Ovid SP
- 5. Table S5 The reasons for the exclusion of full-text articles
- 6. Table S6 Characteristics of the included studies
- 7. Table S7 ARHQ Methodology Checklist for Cross-Sectional Study
- 8. Table S8 Newcastle-Ottawa Scale for Cohort study
- 9. Table S9 Meta-regression analyses of sarcopenia prevalence
- 10. Figure S1 Prevalence of sarcopenia by criteria
- 11. Figure S2 Prevalence of sarcopenia by disease subtype
- 12. Figure S3 Prevalence of sarcopenia by mean age
- 13. Figure S4 Sensitivity analysis
- 14. Figure S5 Egger's test for publication bias

### Table S1 Search strategy by Medline via Ovid SP

- 1. exp Scleroderma, Systemic/
- 2. ((Systemic or general\* or diffus\* or progress\* or Limit\*) adj3 sclerosis).mp.
- 3. scleroderm\*.tw.
- 4. SSc.tw.

- 5. 1 or 2 or 3 or 4
- 6. exp muscular atrophy/
- 7. (sarcopen\* or myopen\* or dynapon\* or amyotroph\* or myoatroph\* or myophagis\* or myodegenerat\*).mp.
- 8. ((muscle or muscular) adj5 (atroph\* or wast\* or weak\* or loss\* or mass or degenerat\*)).ti,ab.
- 9. 6 or 7 or 8
- 10. 5 and 9
- 11. exp animals/ not humans.sh.
- 12. 10 not 11

### Table S2 Search strategy by Embase via Ovid SP

- 1. exp systemic sclerosis/
- 2. ((Systemic or general\* or diffus\* or progress\* or Limit\*) adj3 sclerosis).mp.
- 3. scleroderm\*.tw.
- 4. SSc.tw.
- 5. 1 or 2 or 3 or 4
- 6. exp muscle atrophy/
- 7. (sarcopen\* or myopen\* or dynapon\* or amyotroph\* or myoatroph\* or myophagis\* or myodegenerat\*).mp.
- 8. ((muscle or muscular) adj5 (atroph\* or wast\* or weak\* or loss\* or mass or degenerat\*)).ti,ab.
- 9. 6 or 7 or 8
- 10. 5 and 9
- 11. exp animal/
- 12. human/
- 13. 11 not 12
- 14. 10 not 13

Topic= (((Systemic or general\* or diffus\* or progress\* or Limit\*) near/3 sclerosis) or sclerodem or ssc) and (sarcopen\* or myopen\* or dynapon\* or amyotroph\* or myoatroph\* or myophagis\* or myodegenerat\* or ((muscle or muscular) near/5 (atroph\* or wast\* or weak\* or loss\* or mass or degenerat\*)))

### Table S4 Search strategy by Cochrane Central Register of Controlled Trials via

### Ovid SP

- 1. exp Scleroderma, Systemic/
- 2. ((Systemic or general\* or diffus\* or progress\* or Limit\*) adj3 sclerosis).mp.
  - . scleroderm\*.tw.
- 4. SSc.tw.
- 5. 1 or 2 or 3 or 4
- 6. exp muscular atrophy/
- 7. (sarcopen\* or myopen\* or dynapon\* or amyotroph\* or myoatroph\* or myophagis\* or myodegenerat\*).mp.
- 8. ((muscle or muscular) adj5 (atroph\* or wast\* or weak\* or loss\* or mass or degenerat\*)).ti,ab.
- 9. 6 or 7 or 8
- 10. 5 and 9

Table S5 The reasons for the exclusion of full-text articles

Study	Reason for the exclusion
Norman (2014)	Repeated study
Siegert (2014)	Repeated study
Caimmi (2017)	Repeated study
March (2017)	Repeated study
Doerfler (2017)	Intervention study
Paolino (2018)	Repeated study
Radic (2018)	Not reported sarcopenia prevalence data
	in SSc patients
Remolina (2019)	Repeated study
Sari (2019)	Repeated study
Veronica (2019)	Repeated study
Hax (2020)	Repeated study
Santo (2020)	Repeated study
Sangaroon (2020)	Repeated study
Peterson (2020)	Not reported sarcopenia prevalence data
	in SSc patients
Efremova (2021)	Repeated study
Sorokina (2022)	Not reported sarcopenia prevalence data
	in SSc patients

							BMJ Open			bmjoper			Page 38 of 48
1 2 3 4										bmjopen-2023-078034 by copyright, includi			
	irst author and rear	Country	Study design	Sample size	Mean age(years)	Female,	Disease subtype	Disease duration (years)	SSc diagnostic criteria	aropenia March 2024. I Ing for uses related	Criteria (assessment method detecting sarcopenia)	Prevalence sarcopenia of	of
12 13					04					Downloa ent Sup to text		Total,n(%)	Diffuse,n( %)
14 15 16 17 18 19 20 21 22	Efremova (2022)	Russia	study Cross-sectional study	47	53.9	47	limited 29 diffuse 18	6	2013 ACR/EULAR	nloaded from http://mmjops hupe和eur (ABES) .20 sxt and data minng, Al trai	LMS (HGS) LMM (DXA) LMS (HGS and Chair rising test) LPP (GS and	10(21.3%)	6(12.8%)
23 24 25 26 27 28	Sangaroon (2022)	Thailand	Cross-sectional study	180	58.8	119	limited 86 diffuse 94	6.2	0,	ng, Al training, and similar t	SPPB) LMM(DXA) LMS(HGS) LPP(GS)	41(22.8%)	30(16.7 %)
29 30 31	A		College of Rheumato							kental Muscl			
32 33	W	orking Group o	on Sarcopenia in Old	People; HG	S, hand grip stren	ngth; 4mGS,	4 m gait speed;	SPPB, Shor	t Physical Perfor	magice Battery	y; GS, gait speed; A	WGS, Asian	
34 35 36 37 38 39 40 41 42	W	orking Group f	or Sarcopenia.							Agence Bibliographique de l			
43 44				Fo	r peer review or	nly - http://br	njopen.bmj.cor	m/site/abou	ıt/guidelines.xht	ml —			

Page 38 of 48

Table S7 ARHQ Methodology Checklist for Cross-Sectional Study

Study	Ite	Ite	Ite	Ite	Ite	Ite	Ite	Ite	Ite	Ite	Ite	Total
	m 1	m 2	m 3	m 4	m 5	m 6	m 7	m 8	m 9	m	m	Score
										10	11	
Caimmi (2018)	Yes	Yes	Yes	Yes	Unc	Yes	No	No	Unc	Yes	No	6
					lear				lear			
Siegert (2018)	Yes	Yes	Unc	Yes	Unc	Yes	No	No	No	Yes	No	5
			lear		lear							
Corallo (2019)	Yes	Yes	Yes	Yes	Unc	Yes	No	No	No	Yes	No	6
					lear							
Rincon (2019)	Yes	Yes	Unc	Unc	Unc	Yes	No	No	No	Yes	No	4
			lear	lear	lear							
Hax (2021)	Yes	Yes	Yes	Yes	Unc	Yes	Yes	No	Yes	Yes	No	8
					lear							
Sari (2021)	Yes	Yes	Yes	Yes	Unc	Yes	No	No	No	Yes	No	6
					lear							
Efremova	Unc	Yes	Unc	Unc	Unc	Yes	No	No	No	Yes	No	3
(2022)	lear		lear	lear	lear							
Sangaroon	Yes	Yes	Yes	Yes	Unc	Yes	No	No	No	Yes	No	6
(2022)					lear							

- Item 1. Define the source of information (survey, record review)
- Item 2. List inclusion and exclusion criteria for exposed and unexposed subjects (cases and controls) or refer to previous publications
- Item 3. Indicate time period used for identifying patients
- Item 4. Indicate whether or not subjects were consecutive if not population-based
- Item 5. Indicate if evaluators of subjective components of study were masked to other aspects of the status of the participants
- Item 6. Describe any assessments undertaken for quality assurance purposes (e.g., test/retest of primary outcome measurements)
- Item 7. Explain any patient exclusions from analysis
- Item 8. Describe how confounding was assessed and/or controlled
- Item 9. If applicable, explain how missing data were handled in the analysis
- Item 10. Summarize patient response rates and completeness of data collection
- Item 11. Clarify what follow-up, if any, was expected and the percentage of patients for which incomplete data or follow-up was obtained


### Table S8 Newcastle-Ottawa Scale for Cohort study

Study	Selection				Comparability	arch 2024. Ensagner Ses Selate			Total Score
	Representativeness of the exposed cohort	Selection of the non-exposed cohort	Ascertainment of exposure	Demonstration that outcome of interest was not present at start of study	Comparability of cohorts on the basis of the design or analysis	A. Downloaded from http://lement Superieur (ABES) . ed to text and data mining,	Was follow-up long enough for outcomes to occur	Adequacy of follow up of cohorts	
Paolino (2020)	0	1	1	0	1	), Al train	0	0	4
					en o,	n.bmj.com/ on June 8, 2025 at Agence Bibliographique de l ing, and similar technologies.			

Table S9 Meta-regression analyses of sarcopenia prevalence


	J	v			
Variables	Coefficient	SE	P value	CI-Lower	CI-Upper
Sample size	-0.0022	0.0026	0.424	-0.0083	0.0039
Average age	0.0210	0.0319	0.532	-0.0545	0.0965
Proportion of	-1.0603	1.3233	0.449	-4.1893	2.0687
female					
Duration of	-0.0606	0.0488	0.255	-0.1760	0.0549
SSc					

Figure S1 Prevalence of sarcopenia by criteria




ES = effect size (prevalence);  $I^2 = I^2$  heterogeneity statistic. A random effects model was used for analysis, and there was no significant difference between subgroups (P = 0.234).

Figure S2 Prevalence of sarcopenia by disease subtype



ES = effect size (prevalence);  $I^2 = I^2$  heterogeneity statistic. The random effects model was used for the analysis, and there was no significant difference between the subgroups (P = 0.339).

Figure S3 Prevalence of sarcopenia by mean age



ES = effect size (prevalence);  $I^2 = I^2$  heterogeneity statistic. The random effects model was used for the analysis, and there was no significant difference between the subgroups (P = 0.539).

Figure S4 Sensitivity analysis





Figure S5 Egger's test for publication bias





# PRISMA 2020 Checklist

ge 47 of 48		BMJ Open BMJ Open	
PRISM	/A 20	by comjopen-2020 Checklist	
Section and Topic	Item #	Checklist item	Location where item is reported
TITLE		<u>c. 34</u> 59 c	13 reported
Title	1	Identify the report as a systematic review.	Pg. 1, lines 1-2
ABSTRACT		SET CHARGE CONTRACTOR OF THE CO	
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	Pg. 2
INTRODUCTION		att	
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	Pg. 5, lines 1-11
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	Pg. 5, lines 13-15
METHODS		2 6 6	
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	Pg. 6, lines 7-18
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted identify studies. Specify the date when each source was last searched or consulted.	Pg. 5, lines 18-22; Pg. 6, lines 1-5
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used	Table S1-4
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how make review reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	Pg. 7, lines 7-12
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each epoch, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	Pg. 7, lines 12-19
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with act outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which study were sought (e.g. for all measures).	Pg. 6, lines 20-22; Pg. 7 lines 1-3
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, and by sources). Describe any assumptions made about any missing or unclear information.	Table S6 and Figure 3
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how name in previewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	Pg. 7, lines 21-22; Pg. 8 lines 1-6
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	Pg. 8, lines 12-16
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	Figure 2-3
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing sumary statistics, or data conversions.	Pg. 7, lines 17-19
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses timi	Pg. 8, lines

# PRISMA 2020 Checklist

	•	ight 2023	
Section and Topic	Item #	Checklist item	Location where item is reported
		ng o	10-12
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used s	Pg. 8, lines 8-16
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup and best and second study results (e.g. subgroup and second study results (e.g. subgro	Pg. 8, lines 21-22; Pg. lines 7-8
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	Pg. 9, lines 10-11
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting (asses).	Pg. 9, lines 12-13
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	None
RESULTS		3 8 3	
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to t	Figure 1
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they w≇e excluded.	Figure 1, Table S5
Study characteristics	17	Cite each included study and present its characteristics.	Table S6
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	Table S7-8
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) a effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	Figure 2-3, Figure S1-3
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	Figure 2-3, Figure S1-3
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summare estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	Pg. 11, lines 3-20
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	Figure S1- 3, Table S9
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	Pg. 13, lines 6-7, Figure S4
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	Pg. 13, lines 6-7
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	None
DISCUSSION		de	
Discussion	23a	Provide a general interpretation อาการค่องอาการที่สายรถเร็งเก ให้เลืองให้เหมืองโดยเกี่ยงเดืองโดยเกี่ยงให้เลืองโดยเกี่ยงให้เลืองโดยเกี่ยงให้เลืองโดยเกี่ยงให้เลืองโดยเกี่ยงให้เลืองโดยเกี่ยงให้เลืองโดยเกี่ยงให้เลืองโดยเกี่ยงให้เลืองโดยเกี่ยงให้เลืองโดยเกี้ยงให้เลืองโดยเกี่ยงให้เลืองโดยเกียงให้เลืองโดยเกี่ยงให้เลืองโดยเกี่ยงให้เลืองโดยเกี่ยงให้เลืองโดยเกี่ยงให้เลืองโดยเกี่ยงให้เล้ยเกี่ยงให้เลืองโดยเกี่ยงให้เลืองโดยเกี่ยงให้เลืองโดยเกี่ยงให้เลืองโดยเกี่ยงให้เลืองโดยเกี่ยงให้เลืองโดยเกี่ยงให้เลืองโดยเกี่ยงให้เลืองโดยเกี่ยงให้เลืองโดยเกี่ยงให้เลืองโดยเกี่ยงให้เลืองโดยเกี่ยงให้เลืองโดยเกี่ยงให้เลืองโดยเกี่ยงให้เลืองโดยเกี่ยงให้เลืองโดยเกี่ยงให้เล้าเลืองโดยเกี่ยงให้เล้ยเกี่ยงให้เลืองโดยเกี่ยงให้เลืองโดยเกี่ยงให้เล้ยเกี่ยงให้เล้ยเกี่ยงให้เล้ยเกี่ยงให้เล้ยเกี่ยงให้เล้ยเกี่ยงให้เล้ยเกี่ยงให้เล้ยเกี่ยงให้เล้ยเกี่ยงให้เล้ยเกี่ยงให้เล้ยเกี่ยงให้เล้ยเกี่ยงให้เล้ยเกียงให้เล้ยเกี่ยงให้เล้ยเกียงให้เล้ยเก	Pg. 14,

cted by copyrigh

## PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
		Discuss any limitations of the evidence included in the review.	lines 19-22; Pg. 15, lines 1-22; Pg. 16 lines 1-9
	23b	Discuss any limitations of the evidence included in the review.	Pg. 15, lines 6-7
	23c	Discuss any limitations of the review processes used.	Pg. 17, lines 9-20
	23d	Discuss any limitations of the review processes used.  Discuss implications of the results for practice, policy, and future research.  Discuss implications of the results for practice, policy, and future research.	Pg. 16, lines 11-22; Pg. 17 line 1
OTHER INFORMA	TION	3 8 3	
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the value was not registered.	Pg. 5, lines 18-20
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	Pg. 5, lines 18-20
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	None
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	Page 18, lines 11-20
Competing interests	26	Declare any competing interests of review authors.	Page 18, lines 21-22
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	Table S6, Figure 2-3, Figure S1-3
From: Page MJ, McKi	enzie JE,	Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic For more information, visit: <a href="http://www.prisma-statement.org/">http://www.prisma-statement.org/</a> Bibliographique de I	10.1136/bmj.n71
		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

# **BMJ Open**

# Sarcopenia in Systemic Sclerosis: Prevalence and Impact - A Systematic Review and Meta-analysis

Journal:	BMJ Open
Manuscript ID	bmjopen-2023-078034.R2
Article Type:	Original research
Date Submitted by the Author:	01-Feb-2024
Complete List of Authors:	Tu, Xiangping; Sichuan University West China Hospital, Department of Geriatrics; Sichuan University West China Hospital, National Clinical Research Center for Geriatrics Lin, Taiping; Sichuan University West China Hospital, Department of Geriatrics; Sichuan University West China Hospital, National Clinical Research Center for Geriatrics Ju, Yuan; Sichuan University, Sichuan University library Shu, Xiaoyu; Sichuan University West China Hospital, Department of Geriatrics; Sichuan University West China Hospital, National Clinical Research Center for Geriatrics Jiang, Tingting; Sichuan University West China Hospital, Department of Geriatrics; Sichuan University West China Hospital, National Clinical Research Center for Geriatrics Ge, Ning; Sichuan University West China Hospital, National Clinical Research Center for Geriatrics Yue, Jirong; Sichuan University West China Hospital, Department of Geriatrics; Sichuan University West China Hospital, National Clinical Research Center for Geriatrics
<b>Primary Subject Heading</b> :	Diagnostics
Secondary Subject Heading:	Epidemiology, Geriatric medicine, Rheumatology
Keywords:	Rheumatology < INTERNAL MEDICINE, GERIATRIC MEDICINE, Systematic Review

SCHOLARONE™ Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1	
2	
2	
2	
4	
5	
6	
7	
,	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
ンソ	

1	Sarcopenia in Systemic Sclerosis: Prevalence and Impact - A Systematic Review and
2	Meta-analysis
3	Xiangping Tu, <sup>1</sup> Taiping Lin, <sup>1</sup> Yuan Ju, <sup>2</sup> Xiaoyu Shu, <sup>1</sup> Tingting Jiang, <sup>1</sup> Ning Ge, <sup>1</sup> Jirong Yue <sup>1*</sup>
4	<sup>1</sup> Department of Geriatrics and National Clinical Research Center for Geriatrics, West China
5	Hospital, Sichuan University, Chengdu Sichuan, China, <sup>2</sup> Sichuan University Library, Chengdu
6	Sichuan, China.
7	Correspondence to: Dr. Jirong Yue, Department of Geriatrics, West China Hospital, Sichuan
8	University, Chengdu Sichuan, 610041, China, <u>yuejirong11@hotmail.com</u> ; Telephone
9	+8618980601143.
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	

#### 1 Abstract

- **Objective** This review aims to provide an estimate of sarcopenia prevalence and its impact
- 3 on clinical characteristics in patients with systemic sclerosis (SSc).
- **Design** Systematic review and meta-analysis.
- 5 Data sources Embase, Medline, Web of Science, and the Cochrane Central Register of
- 6 Controlled Trials were systemically searched from inception to May 24, 2023.
- 7 Eligibility criteria for selecting studies We included observational studies that reported the
- 8 prevalence of sarcopenia in patients with SSc.
- 9 Data extraction and synthesis Two reviewers independently performed study selection and
- data extraction using standardized methods. Risk of bias was assessed using the Agency for
- Healthcare Research and Quality (AHRQ) scale and the Newcastle–Ottawa Scale
- 12 (NOS). Meta-analysis was conducted using random effects models.
- **Results** A total of 4583 articles were screened and 9 studies with data from 815 patients were
- included in the analysis (8 cross-sectional studies and 1 retrospective cohort study). The
- overall prevalence of sarcopenia in SSc patients was 22% [95% confidence interval (CI) 17%
- to 28%]. SSc patients with sarcopenia had a poorer quality of life [mean difference (MD) -
- 17 12.02; 95% CI -19.11 to -4.93] and higher CRP levels [standardized mean difference (SMD)
- 18 0.67; 95% CI 0.35 to 1.00].
- 19 Conclusions Sarcopenia is common in patients with SSc. SSc patients with sarcopenia had a
- 20 worse quality of life and higher CRP levels, based on our findings. Given the detrimental
- 21 impact of sarcopenia on quality of life, future efforts aimed at early identification of sarcopenia
- in the clinical assessment of patients with SSc may have significance.

- **Keywords** Sarcopenia; Systemic sclerosis; Meta-analysis; Prevalence
- 3 Strengths and limitations of this study
- 4 This is the first systematic review and meta-analysis to evaluate the prevalence and impact of
- 5 sarcopenia in patients with systemic sclerosis.
- 6 We conducted a comprehensive literature search to ensure that all eligible studies were
- 7 included in the analysis.
- 8 We could not establish a definitive causal relationship between sarcopenia and systemic
- 9 sclerosis.
- 10 Even though this review included studies from different continents (Europe, South America,
- and Asia), data on participant race were not accessible, limiting its potential applicability to
- 12 specific patient subgroups.

#### Introduction

Systemic sclerosis (SSc) is a rare immune-mediated rheumatic disease that is characterized by inflammation, microvascular damage, and progressive fibrosis of both the skin and internal organs, such as the gastrointestinal tract, lung, heart, and kidney.[1,2] Depending on the extent of cutaneous involvement, SSc can be classified as limited cutaneous SSc (lcSSc) or diffuse cutaneous SSc (dcSSc).[3] Patients with SSc are at risk for body composition abnormalities, including loss of skeletal muscle mass, due to malnutrition resulting from gastrointestinal involvement, chronic inflammation, and steroid therapy. [4–7] In addition, heart, lung, and joint involvement in SSc patients can lead to impaired exercise ability and decreased physical activity.[8] These factors are closely related to sarcopenia, which is an age-related disease characterized by progressive and generalized loss of skeletal muscle mass and strength.[9] The coexistence of sarcopenia and SSc can exacerbate the patient's health issues and increase their healthcare costs, posing significant challenges for healthcare professionals. According to a meta-analysis, the prevalence of sarcopenia in community-dwelling elders aged over 60 years was 11% [95% confidence interval (CI) 8% to 13%] in men and 9% (95% CI 7% to 11%) in women.[10] The presence of sarcopenia increases the risk of falling, functional decline, frailty, and mortality, leading to poor quality of life and significant healthcare expenses.[11] The high prevalence of sarcopenia in older adults, combined with its detrimental consequences, warrants the need for effective prevention and management strategies. In SSc patients, addressing sarcopenia may improve their functional status and overall health outcomes, highlighting the importance of early screening and intervention. Healthcare professionals need to recognize the interplay between SSc and sarcopenia to provide optimal

1 care for these patients.

- 2 In recent years, the presence of sarcopenia in SSc has garnered attention in several studies.[4–
- 3 7,12–16] The documented prevalence of sarcopenia in SSc varies widely from 10.7% to 42%
- 4 among different studies, which can be attributed to several factors.[4,5] Differences in
- 5 diagnostic criteria and assessment methods utilized in various studies, such as those proposed
- 6 by the European Working Group of Sarcopenia in Older People (EWGSOP)[9,17] and the
- 7 Asian Working Group for Sarcopenia (AWGS),[18] can result in variations in the evaluation
- 8 of muscle mass in patients. Furthermore, the influence of sarcopenia on the clinical features of
- 9 SSc patients has been a topic of debate. For instance, Caimmi et al.[12] suggested that
- 10 individuals with SSc and sarcopenia had a longer duration of disease; the longer disease
- duration means that patients live longer with the disease, while Siegert et al.[6] contradicted
- this claim and found no difference between sarcopenia and disease duration in SSc patients.
- 13 Currently, no comprehensive systematic review or meta-analysis has examined sarcopenia in
- SSc. Therefore, we conducted a systematic review and meta-analysis to identify the diagnostic
- criteria for sarcopenia and evaluate the most reliable evidence on the prevalence of sarcopenia
- in SSc patients, as well as the effect of sarcopenia on the clinical features of SSc patients.

### 17 Methods

# Data sources and search strategy

- 19 This systematic review and meta-analysis was conducted following the Preferred Reporting
- 20 Items for Systematic Reviews and Meta-analyses (PRISMA) guideline[19] and registered in
- 21 PROSPERO (CRD42022368326). We systemically searched four electronic databases,
- 22 including Embase, Medline, Web of Science, and the Cochrane Central Register of Controlled

- 1 Trials, to identify all relevant articles relating to sarcopenia and SSc, without language
- 2 restrictions. Our search encompassed all records published from inception to May 24, 2023,
- 3 utilizing the following terms: 'systemic sclerosis', 'scleroderm\*', 'SSc', 'muscular atrophy',
- 4 'sarcopen\*' and 'myopen\*' (Supporting Information, Table S1-4). Additionally, we conducted
  - a manual search of the reference lists of the included articles to identify potential studies that
- 6 may have been overlooked by the principal search.

#### Inclusion and exclusion criteria

- 8 The following inclusion and exclusion criteria were employed for this systematic review and
- 9 meta-analysis: (1) studies conducted exclusively on adult patients (age >18 years) diagnosed
- with SSc; (2) studies reporting the prevalence of sarcopenia in SSc patients; (3) studies defining
- sarcopenia as low muscle mass (LMM) plus low muscle strength (LMS), and/or low physical
- 12 performance (LPP), or LMM alone; LMM was evaluated by dividing appendicular skeletal
- muscle mass (in kilograms) by height in meters squared, LMS by hand grip strength, LPP by
- 14 gait speed or short physical performance battery, and diagnostic cutoffs varied depending on
- the criterion[9,17,18,20]; (4) studies measuring lean mass or muscle mass using one of the four
- main techniques: dual-energy X-ray absorptiometry (DXA), bioelectrical impedance analysis
- 17 (BIA), magnetic resonance imaging (MRI) and computed tomography (CT); and (5)
- observational studies. Conversely, the exclusion criteria were as follows: repeated studies
- 19 (defined as either identical data or identical articles).

#### 20 Outcomes

- 21 The main outcomes of this systematic review comprise two aspects: firstly, the prevalence of
- 22 sarcopenia among patients with SSc, and secondly, the clinical features of patients with SSc

2 encompassed a range of factors, namely, the duration of disease, the quality of life assessed by

the Short Form-36 (SF-36) survey[21], the pulmonary function (the forced vital capacity (FVC)

predicted value), and the C-reactive protein (CRP) level. These features are frequently the focus

of clinical studies in patients with SSc, and it is of significant interest to understand how

sarcopenia impacts them.

# Study selection and data extraction

8 After removing duplicates, the studies identified through the search strategy underwent

9 eligibility assessment by two reviewers (X.T. and T.L.), who independently screened the titles

and abstracts and assigned them to one of three categories: 'include,' 'exclude,' or 'maybe.'

Subsequently, the full-text articles of those categorized as 'include' or 'maybe' were reviewed

to arrive at a final selection, with any discrepancies between the reviewers resolved by a third

reviewer (J.Y.). Two reviewers (X.T. and X.S.) independently extracted the following variables

using a pre-defined data collection form: first author, publication year, country, study design,

sample size, mean age, number of females, disease subtype, mean disease duration, SSc

diagnostic criteria, sarcopenia diagnostic criteria, assessment method for detecting sarcopenia,

and prevalence of sarcopenia. Additionally, we also collected data on clinical features in the

form of mean ± standard deviation (SD). For those studies that were not expressed as mean

19 ± SD, we performed data conversion with the method recommended by Luo et al.[22] and

20 Wan et al.[23]

#### 21 Assessment of quality

22 Two authors (X.T. and T.J.) independently assessed the quality of the included studies using

- the Agency for Healthcare Research and Quality (AHRQ)[24] scale in cross-sectional studies.
- 2 This tool consists of 11 questions, with a 'no' or 'unclear' receiving 0 points and a 'yes' receiving
- 3 1 point. Low-quality articles received scores of 0–3, moderate-quality scores of 4–7, and high-
- 4 quality scores of 8–11. The Newcastle–Ottawa Scale (NOS) was used to judge the quality of
  - the cohort study.[25] The NOS scoring system assigns points from 0 to 9. We assigned values
- 6 ranging from 0 to 3, 4 to 6, and 7 to 9 for low, moderate, and high-quality, accordingly. Any
- 7 discrepancies were resolved through discussion or consensus with a third author (J.Y.).

# Statistical Analysis

- 9 The prevalence of sarcopenia in SSc patients was determined by calculating the proportion of
- patients with sarcopenia in each study and conducting a meta-analysis of single proportions.
- We performed this meta-analysis using Stata/SE (Version 12.0, StataCorp, Texas, USA).
- Forest plots were used to illustrate the prevalence of sarcopenia, along with corresponding 95%
- confidence intervals (CIs) for each study and the overall estimate. Clinical characteristics such
- as disease duration, the SF-36 value, the FVC predicted value, and the CRP level from studies
- that compared SSc patients with and without sarcopenia were also analyzed using Review
- Manager (Version 5.4, The Cochrane Collaboration, Oxford, UK) and expressed as mean
- difference (MD) or standardized mean difference (SMD) with 95% CI. Heterogeneity across
- studies was assessed via the I<sup>2</sup> statistic, with values of 25% being considered low, 50%
- moderate, and 75% high.[26] Considering the variation in the definition of sarcopenia,
- 20 diagnostic criteria, and population characteristics among the included studies, this study
- 21 employed a random-effects model.
- 22 Subgroup analyses were conducted to investigate potential sources of heterogeneity, focusing

on sarcopenia definition (1 vs >1 diagnostic criteria), disease subtype, and mean age (< 60 vs ≥60 years). The reasons for grouping in subgroup analysis are as follows. Firstly, variability in the definition of sarcopenia will result in varied prevalence estimates for patients with SSc. Unsurprisingly, increasing the number of necessary criteria in a sarcopenia definition will eventually diminish sarcopenia prevalence. Additionally, the disease subtype is an important factor that affects the prevalence of sarcopenia. Patients with dcSSc are more prone to develop sarcopenia.[14] Moreover, age is an essential factor that influences the onset and course of sarcopenia, with the prevalence of sarcopenia increasing with age. Meta-regressions were also conducted on sample size, mean age, percentage of female patients, and duration of SSc. However, due to limited data on the clinical characteristics of SSc patients with and without sarcopenia, subgroup analyses and meta-regressions were not conducted. To evaluate the stability of pooled results, sensitivity analysis was performed by excluding one study at a time. Publication bias was evaluated using Egger's test[27]. Statistical significance was set at P < 0.05 for all analyses.

# Patient and public involvement

- Patients and/or the public were not involved in the design, conduct, reporting, or dissemination
- plans of this research.

#### **Results**

#### Search results

- A comprehensive search of databases yielded 4583 articles. After eliminating duplicates (n =
- 1523), the remaining 3060 titles and abstracts were screened. Subsequently, 25 relevant articles
- underwent full-text reading, and 16 were excluded for reasons specified in the flow chart and

- 1 Table S5 in the supplement. Ultimately, 9 studies were eligible for inclusion in this meta-
- 2 analysis (Figure 1).

# 3 Study characteristics

- 4 Table S6 provides an overview of the characteristics of the studies included in this meta
  - analysis. A total of 815 SSc patients from 9 eligible studies[4–7,12–16] published between
- 6 2018 and 2022 were included. The mean age of the patients ranged from 52.5 to 64.1 years,
- 7 while the mean duration of SSc ranged from 6 to 12.8 years. The majority of the studies (8 out
- 8 of 9) had a cross-sectional design,[4–6,12–16] with one being a retrospective cohort study.[7]
- 9 The studies were conducted in various regions, with five from Europe,[5–7,12,16] two from
- 10 South America,[13,15], and two from Asia.[4,14]

# 11 Risk of bias

- According to the AHRQ and NOS ratings, 8 of the eligible studies[4–7,12,14–16] were of
- moderate quality, with only one article[13] classified as high quality. (Table S7-8 in the
- 14 supplement).

# 15 Methods used to assess sarcopenia

- Table S6 provides an overview of the diagnostic criteria used to evaluate sarcopenia across the
- included studies. Among them, seven studies[4–7,13,15,16] employed EWGSOP criteria (5
- 18 EWGSOP 2010 and 2 EWGSOP 2019) while one[14] used AWGS criteria. Three
- studies[5,7,12] solely relied on LMM for sarcopenia diagnosis, while six studies[4,6,13–16]
- 20 utilized LMM combined with LMS and/or LPP. The sarcopenia diagnostic criteria and cutoff
- values in the studies are summarized in Table 1. Muscle mass was measured using dual-energy
- 22 X-ray absorptiometry in seven studies [5,7,12–16] and bioelectrical impedance analysis in two

- 2 studies[4,6,13–16], while gait speed (three studies[14–16]) and the short physical performance
- 3 battery (SPPB) (two studies[13,16]) were used to evaluate physical performance.
- 4 Sarcopenia prevalence

- 5 Overall sarcopenia prevalence
- 6 The nine studies included in this review reported the prevalence of sarcopenia in SSc patients,
- 7 ranging from 10.7% to 42% (Table S6). The pooled prevalence of sarcopenia in patients with
- 8 SSc was estimated at 22% (95% CI 17% to 28%), as shown in Figure 2.
- 9 Subgroup analysis of sarcopenia prevalence
- The prevalence of sarcopenia differed in studies that utilized a single criterion [LMM; 28% (95%)]
- 11 CI 16% to 42%)] versus those that employed >1 criterion [LMM + LMS and/or LPP; 20%
- (95% CI 15% to 25%)], with no statistically significant difference noted (P = 0.234, Figure S1
- in the supplement). Subgroup analysis based on disease subtype revealed that sarcopenia
- 14 prevalence in dcSSc [30% (95% CI 23% to 37%)] was higher than that in lcSSc [23% (95% CI
- 15 12% to 36%)], and the difference was not statistically significant (P = 0.339, Figure S2 in the
- supplement). The United Nations defines an older person as someone above the age of 60.
- 17 Therefore, we also performed a subgroup analysis stratified by the mean age of the participants,
- with < 60 and  $\ge 60$  years as the cutoff points. The prevalence of sarcopenia was lower in
- patients younger than 60 years [20% (95% CI 12% to 29%)] vs those older than 60 years [24%
- 20 (95% CI 17% to 32%)], but the difference was not of statistical significance (P = 0.539, Figure
- 21 S3 in the supplement).
- 22 Meta-regression analyses

- 1 The results of the meta-regression analyses indicated that there was no significant association
- between the prevalence of sarcopenia and sample size (P = 0.424), mean age of patients (P =
- 3 0.532), the proportion of female patients (P = 0.449), or duration of SSc (P = 0.255). These
- 4 findings are summarized in Table S9 of the supplementary material.
- 5 Impact of sarcopenia on the clinical characteristics of SSc patients
- 6 <u>Duration of SSc</u>
- 7 Data from a total of four studies comprising 511 patients were included in the meta-analysis of
- 8 SSc duration, which revealed that individuals with sarcopenia did not have a longer disease
- 9 duration than those without sarcopenia [MD 2.97 years (95% CI -0.13 to 6.08);  $I^2 = 90\%$ ,
- Figure 3A].
- 11 Quality of life
- 12 The meta-analysis included two studies with a total of 191 patients, which provided data on the
- 13 SF-36 value. The findings of the meta-analysis indicated that patients with sarcopenia had a
- lower SF-36 value compared to those without sarcopenia [MD -12.02 (95% CI -19.11 to -4.93);
- $I^2 = 71\%$ , Figure 3B], that is, having sarcopenia was associated with poorer quality of life
- 16 compared with those without sarcopenia.
- 17 <u>Pulmonary function</u>
- The meta-analysis incorporated two studies involving a total of 320 patients that reported data
- on the FVC predicted value. The results indicated that patients with sarcopenia did not have a
- lower FVC predicted value than those without sarcopenia [MD -4.02% (95% CI -8.67 to 0.62);
- $I^2 = 0\%$ , Figure 3C]. Therefore, there was no significant difference in pulmonary function
- between sarcopenia and non-sarcopenia patients.

- 2 Data from two studies comprising 191 patients were analyzed to investigate the relationship
- 3 between sarcopenia and CRP level. The results showed that sarcopenia was associated with a
- 4 higher CRP level than no sarcopenia [SMD 0.67 (95% CI 0.35 to 1.00);  $I^2 = 0\%$ , Figure 3D].
- 5 Sensitivity and publication bias analysis
- 6 The sensitivity analysis revealed that the overall prevalence of sarcopenia was not significantly
- 7 affected by any individual study (Figure S4 in the supplementary material). In addition, Egger's
- 8 test suggested no publication bias in this review (P = 0.311, Figure S5 in the supplement).
- 9 Discussion
- 10 Primary results
- 11 In this meta-analysis encompassing nine studies, the pooled prevalence of sarcopenia among
- 12 815 patients diagnosed with systemic sclerosis (SSc) was estimated to be 22%, which was
- significantly greater than that in community-dwelling older adults.[28] Notably, SSc patients
- 14 diagnosed with sarcopenia had poorer quality of life and a higher CRP level, while no
- significant difference was noted for disease duration and FVC predicted value when compared
- 16 to patients without sarcopenia.

#### 17 Mechanism basis

- 18 Sarcopenia, a condition characterized by loss of muscle mass and function, can be age-
- 19 associated (primary sarcopenia) or secondary to chronic diseases, including malignant tumors
- and musculoskeletal diseases.[29–31] Compared with other chronic inflammatory rheumatic
- 21 diseases, sarcopenia has not been extensively evaluated in SSc. Recently, some studies have
- focused on the presence of sarcopenia in SSc. Nevertheless, the pathogenesis of sarcopenia in

 SSc remains unclear. Possible mechanisms contributing to the development of sarcopenia in SSc include (1) malnutrition: gastrointestinal involvement is the most frequent internal complication of SSc[32]. Symptoms such as esophageal reflux, early satiety, nausea, and vomiting may lead to reduced caloric intake.[12] Additionally, fibrosis of the bowel wall and small intestine bacterial overgrowth can result in malabsorption of nutrients. Therefore, malnutrition is prevalent in SSc patients. One study in community-dwelling older adults demonstrated that malnutrition is an independent predictor of sarcopenia [odds ratio (OR) 2.42; 95% CI 1.04 to 5.60][33]. (2) Oxidative stress and chronic inflammation: oxidative stress, which is an imbalance in oxidant and antioxidant levels, is commonly observed in SSc patients[34]. Increased oxidative stress disrupts the balance between the degradation and resynthesis of skeletal muscle proteins[35]. In addition, chronic low-grade inflammation is detrimental to skeletal muscle in humans[36]. Inflammatory cytokines, such as tumor necrosis factor-α and interleukin-6, have been reported to contribute to the pathogenesis of SSc[37]. These cytokines stimulate protein catabolism and suppress muscle synthesis, ultimately leading to muscle wasting[38]. (3) Physical inactivity: due to pain and joint involvement, physical inactivity is common in SSc patients[39], leading to faster and greater muscle loss[11]. However, the mechanism of sarcopenia in SSc patients remains to be confirmed by future research.

### Interpretation of the results

This review offers unique insight into sarcopenia in patients with SSc. It describes the prevalence of sarcopenia in SSc patients and how it is impacted by the different definitions of sarcopenia. The varying prevalence of sarcopenia may be explained in part by the variety of

 definitions. However, there was no statistical difference between 1 and >1 diagnostic criteria. This might be due to the lack of robustness of the combined results as a result of the small number of studies using one diagnostic criterion. In addition, discrepancies in sarcopenia diagnostic cutoffs among the included studies may have resulted in differing sarcopenia prevalence. Furthermore, our meta-analysis indicated no statistically significant variation in the prevalence of sarcopenia between disease subtypes, which is consistent with the results of Sangaroon et al.[14] It is important to note that this conclusion needs to be interpreted with caution due to the limited number of studies that could be included in the analysis. Although sarcopenia commonly occurs as an age-related process in older individuals[11], it becomes more common as people get older. Our meta-analysis demonstrated that the difference in the prevalence of sarcopenia was not statistically significant between the patients over 60 years old and the patients under 60 years old. Furthermore, patients younger than 60 years old all used >1 criterion to diagnose sarcopenia, which makes the prevalence of sarcopenia in young people even lower. This suggests that, despite the influence of age on the presence of sarcopenia, the illness itself is responsible for sarcopenia onset and progression in SSc patients. Therefore, rheumatologists should screen for sarcopenia even in young SSc patients. However, this conclusion must be confirmed by a large number of high-quality clinical studies. Our meta-analysis also revealed that SSc patients diagnosed with sarcopenia had a poorer quality of life. On the one hand, involvement of the heart, lungs, and joints in SSc patients might result in diminished exercise capacity and decreased physical activity,[8] making SSc patients vulnerable to sarcopenia. On the other hand, sarcopenia is associated with a variety of negative outcomes, including hospitalization, functional decline, falls, and death.[40,41]

 Therefore, it should come as no surprise that SSc patients with sarcopenia have a higher risk of having a worse quality of life. Furthermore, individuals with SSc who had sarcopenia had higher CRP levels, according to our findings. This result is not surprising given that chronic inflammation is a known contributor to secondary sarcopenia.[42] However, our review indicated that no significant difference was noted for disease duration or FVC predicted value between SSc patients with and without sarcopenia. According to the results of Caimmi et al,[12] the longer the disease duration, the greater the risk of sarcopenia. This might be due to the minimal number of studies that could extract data, resulting in false negatives in the pooled study results. Therefore, large prospective cohort studies are required to confirm this conclusion.

# Clinical implications

This meta-analysis provides a comprehensive evaluation of the prevalence, diagnostic criteria, and impact of sarcopenia in SSc patients, which has not been previously done. The results of this study provide an up-to-date estimation of the prevalence of sarcopenia, which can guide sample size calculations for future research. While sarcopenia has been relatively under-studied in SSc compared to other rheumatic diseases, our findings suggested that neither sarcopenia definition, disease subtype nor age affects the prevalence of sarcopenia. SSc patients with sarcopenia had a poorer quality of life, according to our findings. Therefore, early identification and intervention of sarcopenic patients by clinicians is crucial. The high prevalence of sarcopenia in SSc patients highlights the importance of early screening and management. Standardized criteria for sarcopenia diagnosis are also essential in SSc patients to minimize variations in prevalence. These findings have important implications for future research,

2 potentially improve outcomes for these patients.

# Strengths and weaknesses

- 4 This systematic review undertook a comprehensive and meticulous literature search to ensure
  - that all pertinent studies were included in the analysis. The selection of studies, data extraction,
- 6 and quality assessments were carried out independently by two reviewers, thereby enhancing
- 7 the accuracy and reliability of the results. Subgroup analyses and meta-regression analyses
- 8 were also conducted to explore the possible sources of heterogeneity, while sensitivity and
- 9 publication bias analyses were performed to ensure robust and dependable conclusions.
- 10 Nevertheless, we must acknowledge certain limitations of our study. Firstly, since most of the
- 11 included studies were cross-sectional, it is impossible to establish a definitive causal
- 12 relationship between sarcopenia and SSc. Nonetheless, this is a limitation inherent to the
- original literature and beyond our control. We, therefore, look forward to high-quality
- prospective cohort studies to provide more conclusive evidence on this matter. Secondly, there
- was some heterogeneity among the included studies in terms of factors such as the definition
- of sarcopenia, measurement approaches, and diagnostic cut-offs. Moreover, most of the studies
- 17 had small sample sizes. Therefore, future studies should aim to use uniform diagnostic criteria
- 18 for sarcopenia and expand the sample size to improve the quality of research. Finally, even
- 19 though this review included studies from different continents (Europe, South America, and
- Asia), data on participant race were not accessible, limiting its potential applicability to specific
- 21 patient subgroups.

# 22 Conclusions

- 1 Sarcopenia is common in patients with SSc. SSc patients with sarcopenia had a worse quality
- 2 of life and higher CRP levels, based on our findings. Given the detrimental impact of
- 3 sarcopenia on quality of life, future efforts aimed at early identification of sarcopenia in the
- 4 clinical assessment of patients with SSc may have significance.

#### 5 Contributors

- 6 All authors conceived and designed this review; YJ, XPT, and JRY developed the search
- 7 strategy; XPT and TPL screened studies; XPT and XYS extracted data; XPT and TTJ appraised
- 8 study quality; XPT and NG conducted data analysis; XPT drafted the manuscript; all authors
- 9 revised the manuscript for important intellectual content. JRY had full access to all the data in
- the study and took responsibility for the integrity of the data and the accuracy of the data
- 11 analysis.

#### 12 Funding

- 13 This study was supported by grants from the National Key Research and Development Program
- 14 (2020YFC2009004), Sichuan Science and Technology Program (2022YFS0295,
- 15 2022YFG0205, 2023ZYD0173), 1.3.5 project for disciplines of excellence, West China
- Hospital, Sichuan University (ZYJC21005), Health Research of Cadres in Sichuan province
- 17 (SCR2022-101).

#### Role of the Funder:

- 19 The funder of the study had no role in study design, data collection, data analysis, data
- 20 interpretation, or writing of the report.

# 21 Competing interests

None declared.

2 Not required.

- 3 Ethics approval
- 4 Not applicable.
- 5 Data availability statement
- 6 The data are accessible upon reasonable request from the corresponding author.
- 7 Online supplementary material
- 8 Additional supporting information may be found online in the Supporting Information section
- 9 at the end of the article.

#### Reference

- 2 1 Denton CP, Khanna D. Systemic sclerosis. *The Lancet*. 2017;390:1685–99.
- 3 2 Zhong L, Pope M, Shen Y, et al. Prevalence and incidence of systemic sclerosis: A
- 4 systematic review and meta-analysis. International Journal of Rheumatic Diseases.
- 5 2019;22:2096–107.
  - 3 LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification,
  - subsets and pathogenesis. *J Rheumatol*. 1988;15:202–5.
- 8 4 Sari A, Esme M, Aycicek GS, et al. Evaluating skeletal muscle mass with ultrasound in
- patients with systemic sclerosis. *Nutrition*. 2021;84:110999.
- 5 Corallo C, Fioravanti A, Tenti S, et al. Sarcopenia in systemic sclerosis: the impact of
- nutritional, clinical, and laboratory features. *Rheumatol Int*. 2019;39:1767–75.
- 12 6 Siegert E, March C, Otten L, et al. Prevalence of sarcopenia in systemic sclerosis: assessing
- body composition and functional disability in patients with systemic sclerosis. *Nutrition*.
- 14 2018;55–56:51–5.
- 7 Paolino S, Goegan F, Cimmino MA, et al. Advanced microvascular damage associated
- with occurrence of sarcopenia in systemic sclerosis patients: Results from a retrospective
- 17 cohort study. *Clinical and Experimental Rheumatology*. 2020;38 Suppl 125(3):65-72.
- 8 Cuomo G, Santoriello C, Polverino F, et al. Impaired exercise performance in systemic
- 19 sclerosis and its clinical correlations. Scandinavian Journal of Rheumatology.
- 20 2010;39:330–5.
- 9 Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on
- definition and diagnosis: Report of the European Working Group on Sarcopenia in Older
- 23 People. *Age Ageing*. 2010;39:412–23.
- 24 10 Papadopoulou SK, Tsintavis P, Potsaki G, et al. Differences in the Prevalence of
- 25 Sarcopenia in Community-Dwelling, Nursing Home and Hospitalized Individuals. A
- Systematic Review and Meta-Analysis. *J Nutr Health Aging*. 2020;24:83–90.
- 27 11 Cruz-Jentoft AJ, Sayer AA. Sarcopenia. *The Lancet*. 2019;393:2636–46.
- 28 12 Caimmi C, Caramaschi P, Venturini A, et al. Malnutrition and sarcopenia in a large cohort
- of patients with systemic sclerosis. *Clin Rheumatol*. 2018;37:987–97.
- 30 13 Hax V, do Espírito Santo RC, Dos Santos LP, et al. Practical screening tools for sarcopenia
- in patients with systemic sclerosis. *PLoS ONE*. 2021;16(1):e0245683.
- 32 14 Sangaroon A, Foocharoen C, Theerakulpisut D, et al. Prevalence and clinical association
- of sarcopenia among Thai patients with systemic sclerosis. *Sci Rep.* 2022;12:18198.

- 15 Rincón IDR, Alak M, Alsina G, et al. Sarcopenia in systemic sclerosis. Arthritis and Rheumatology. 2019;71(S10):2957–8.
- 16 Efremova AO, Toroptsova NV, Nikitinskaya OA, et al. The frequency of sarcopenia and factors associated with muscle mass in women with systemic scleroderma (Pilot Study).
- Osteoporosis International. 2022;32(S1):S409.
- 17 Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48:16–31.
- 18 Chen LK, Liu LK, Woo J, et al. Sarcopenia in Asia: consensus report of the Asian Working
- Sarcopenia. J AmMed Dir Assoc. 2014;15(2):95-101. for
- 10.1016/j.jamda.2013.11.025

- 19 Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
- 20 Chen LK, Woo J, Assantachai P, et al. Asian Working Group for Sarcopenia: 2019
- Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc.
- 2020;21:300-307.e2.
- 21 Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Medical care*. 1992;30(6):473-83.
- 22 Luo D, Wan X, Liu J, et al. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2018;27:1785–805.
- 23 Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard deviation from the
- sample size, median, range and/or interquartile range. BMC Med Res Methodol.
- 2014;14:135.
- 24 Zeng X, Zhang Y, Kwong JSW, et al. The methodological quality assessment tools for
- preclinical and clinical studies, systematic review and meta-analysis, and clinical practice
- guideline: a systematic review. J Evid Based Med. 2015;8:2–10.
- 25 Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality
- of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–5.
- 26 Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses.
- BMJ. 2003;327:557-60.
- 27 Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple,
- graphical test. BMJ. 1997;315:629–34.
- 28 Simsek H, Meseri R, Sahin S, et al. Prevalence of sarcopenia and related factors in
- community-dwelling elderly individuals. Saudi Med J. 2019;40:568–74.

- 2 Neuroblastoma. *Journal of Surgical Research*. 2019;236:101–5.
- 3 30 Matsunaga T, Miyata H, Sugimura K, et al. Prognostic Significance of Sarcopenia and
- 4 Systemic Inflammatory Response in Patients With Esophageal Cancer. *Anticancer Res.*
- 5 2019;39:449–58.
- 6 31 Laurent MR, Dedeyne L, Dupont J, *et al.* Age-related bone loss and sarcopenia in men. *Maturitas*. 2019;122:51–6.
- 8 32 Clements PJ, Becvar R, Drosos AA, *et al.* Assessment of gastrointestinal involvement. *Clin Exp Rheumatol.* 2003;21(3 Suppl 29):S15-8.
- 10 33 Kurose S, Nishikawa S, Nagaoka T, et al. Prevalence and risk factors of sarcopenia in
- community-dwelling older adults visiting regional medical institutions from the Kadoma
- Sarcopenia Study. *Sci Rep.* 2020;10:19129. doi: 10.1038/s41598-020-76185-0
- 13 34 Doridot L, Jeljeli M, Chêne C, et al. Implication of oxidative stress in the pathogenesis of
- systemic sclerosis via inflammation, autoimmunity and fibrosis. *Redox Biology*.
- 15 2019;25:101122.
- 35 Meng SJ, Yu LJ. Oxidative Stress, Molecular Inflammation and Sarcopenia. *International Journal of Molecular Sciences*. 2010;11:1509–26. doi: 10.3390/ijms11041509
- 18 36 Howard C, Ferrucci L, Sun K, et al. Oxidative protein damage is associated with poor grip
- strength among older women living in the community. *Journal of Applied Physiology*.
- 20 2007;103:17–20.
- 37 Shima Y. Cytokines Involved in the Pathogenesis of SSc and Problems in the Development
   of Anti-Cytokine Therapy. *Cells*. 2021;10:1104.
- 23 38 Bano G, Trevisan C, Carraro S, *et al.* Inflammation and sarcopenia: A systematic review and meta-analysis. *Maturitas*. 2017;96:10–5.
- 25 39 Liem SIE, Meessen JMTA, Wolterbeek R, *et al.* Physical activity in patients with systemic sclerosis. *Rheumatol Int.* 2018;38:443–53.
- 40 Tsekoura M, Kastrinis A, Katsoulaki M, *et al.* Sarcopenia and Its Impact on Quality of
   Life. *Adv Exp Med Biol.* 2017;987:213–8.
- 41 Beaudart C, Rizzoli R, Bruyère O, *et al.* Sarcopenia: burden and challenges for public health. *Arch Public Health*. 2014;72:45.
- 42 Wang C, Bai L. Sarcopenia in the elderly: basic and clinical issues. *Geriatr Gerontol Int*.
   2012;12:388–96.
- 33 43 Baumgartner RN, Koehler KM, Gallagher D, et al. Epidemiology of sarcopenia among the

- 44 Fried LP, Tangen CM, Walston J, *et al.* Frailty in older adults: evidence for a phenotype. *J Gerontol A Biol Sci Med Sci.* 2001;56:M146-156.
- 4 45 Lauretani F, Russo CR, Bandinelli S, *et al.* Age-associated changes in skeletal muscles and their effect on mobility: an operational diagnosis of sarcopenia. *J Appl Physiol* (1985). 2003;95:1851–60.
- 46 Gould H, Brennan SL, Kotowicz MA, *et al.* Total and appendicular lean mass reference ranges for Australian men and women: the Geelong osteoporosis study. *Calcif Tissue Int.* 2014;94:363–72.
- 47 Dodds RM, Syddall HE, Cooper R, *et al.* Grip strength across the life course: normative
   data from twelve British studies. *PLoS One*. 2014;9:e113637.
- 48 Pavasini R, Guralnik J, Brown JC, *et al.* Short Physical Performance Battery and all-cause
   mortality: systematic review and meta-analysis. *BMC Med.* 2016;14:215.
- 49 Cesari M, Kritchevsky SB, Newman AB, *et al.* Added value of physical performance measures in predicting adverse health-related events: results from the Health, Aging And
   Body Composition Study. *J Am Geriatr Soc.* 2009;57:251–9.
- 50 Studenski S, Perera S, Patel K, *et al.* Gait speed and survival in older adults. *JAMA*. 2011;305:50–8.

Table 1 Criteria and cutoff points used to detect sarcopenia in each study

T: / :			
First author	Country	Sarcopenia	Cutoff points
and year		diagnostic criteria	
Caimmi	Italy	SMI	
(2018)[12]	Italy	Sivii	LMM: ASM/height2 < 7.26 kg/m <sup>2</sup> for men
\			1.5501 / 26 5427
			and < 5.50 kg/m <sup>2</sup> for women.[43]
Siegert	Germany	EWGSOP	LMM: ALM/height2 < 7.26 kg/m2 for men
(2018)[6]		(2010)	EIVIVI. 7 EIVI/Height2 \ 7.20 kg/Hi2 for their
	0,		and <5.50 kg/m2 for women.[43]
			LMS: BMI $\leq$ 24, HGS $\leq$ 29 kg; 24.1 $\leq$
			$BMI \le 26, HGS \le 30 \text{ kg}; 26.1 \le BMI \le 28,$
			$  HGS \le 30 \text{ kg; BMI} > 28, HGS \le 32 \text{ kg}  $
		`O.	for men. BMI $\leq$ 23, HGS $\leq$ 17 kg; 23.1 $\leq$
			$BMI \le 26, HGS \le 17.3 \text{ kg}; 26.1 \le BMI \le$
			29, HGS ≤ 18 kg; BMI > 29, HGS ≤ 21
			kg for women.[44]
Corallo	Italy	EWGSOP	LMM: RSMI < 7.26 kg/m2 for men and <
(2019)[5]		(2010)	
Rincon	Argentin	EWGSOP	5.50 kg/m2 for women.[43]
(2019)[15]	a	(2010)	LMM: RSMI < 7.26 kg/m2 for men and <
(2017)[10]	$(2017)[13]$ $\alpha$ $(20$		5.50 kg/m2 for women.[43]
			LMS: HGS< 30 kg for men and< 20 kg for
			women.[45]
			LPP: GS< 0.8 m/s (both genders).[45]
Paolino	Italy	EWGSOP	LMM: RSMI < 7.26 kg/m2 for men and <
(2020)[7]		(2010)	
Hax (2021)	Brazil	EWGSOP	5.50 kg/m2 for women.[43]
11uA (2021)	DIGELL	(2019)	LMM: ASMI $< 7.0 \text{ kg/m}^2$ for men and $< 5.5$
		,	kg/m <sup>2</sup> for women.[46]
			LMS: HGS < 27 kg for men and < 16 kg for
			women.[47]
	•		

D:			G
First author	Country	Sarcopenia	Cutoff points
and year		diagnostic	
		criteria	
			LPP: SPPB $\leq 8$ point score.[48]
Sari (2021)[4]	Turkey	EWGSOP (2010)	LMM: ASMI < 7.26 kg/m2 for men and
			<5.50 kg/m2 for women.[43]
			LMS: BMI $\leq$ 24, HGS $\leq$ 29 kg; 24.1 $\leq$ BMI $\leq$ 26, HGS $\leq$ 30 kg; 26.1 $\leq$ BMI $\leq$ 28,
			HGS $\leq 30 \text{ kg}$ ; BMI > 28, HGS $\leq 32 \text{ kg}$
	O,		for men. BMI \(\leq 23\), HGS \(\leq 17\) kg; 23.1 \(\leq \) BMI \(\leq 26\), HGS \(\leq 17.3\) kg; 26.1 \(\leq \)BMI \(\leq \)
		4	29, HGS ≤ 18 kg; BMI > 29, HGS ≤ 21
			kg for women.[44]
Efremova (2022)[16]	Russia	EWGSOP (2019)	LMM: ASMI < 7.0 kg/m <sup>2</sup> for men and < 5.5
(= = = )[1 ]		(2011)	kg/m² for women.[46]
			LMS: HGS < 27 kg for men and < 16 kg for women.[47] or Chair stand > 15 s for
			women.[47] or Chair stand 2 13 3 for
			five rises.[49] LPP: $GS \le 0.8 \text{ m/s.}[50]$ or $SPPB \le 8 \text{ point score.}[48]$
Sangaroon (2022)[14]	Thailand	AWGS (2019)	LMM: ASMI < 7.0 kg/m <sup>2</sup> for men and < 5.4
(2022)[14]		(2017)	kg/m² for women.[20]
			LMS: HGS < 28 kg for men and < 18 kg for
			women.[20]
			LPP: GS< 1 m/s (both genders).[20]

SMI, Skeletal Muscle Mass Index; ASM, appendicular skeletal muscle mass; ALM, appendicular lean mass; RSMI, Relative Skeletal Muscle Mass Index; ASMI, Appendicular Skeleton Muscle Index; SPPB, Short Physical Performance Battery; GS, gait speed.

### Figure legend

- 1. Figure 1 The flow chart of the literature selection
- 2. Figure 2 The pooled prevalence of sarcopenia in SSc patients
- 3. Figure 3 Impact of sarcopenia on clinical characteristics in patients with SSc



Figure 1 The flow chart of the literature selection  $146x170mm (300 \times 300 DPI)$ 




Figure 2 The pooled prevalence of sarcopenia in SSc patients  $146 \times 107 \text{mm} (300 \times 300 \text{ DPI})$ 

	Sar	copen	ia	No sa	rcope	nia		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Caimmi 2018	16	8	29	12	7	111	22.1%	4.00 [0.81, 7.19]	
Corallo 2019	11.86	2.52	26	6	1.42	36	27.9%	5.86 [4.79, 6.93]	-
Sangaroon 2022	6.64	5.17	41	6.11	5.31	139	26.3%	0.53 [-1.28, 2.34]	-
Siegert 2018	9.45	6.42	29	8.12	6.8	100	23.7%	1.33 [-1.36, 4.02]	
Total (95% CI)			125			386	100.0%	2.97 [-0.13, 6.08]	
Heterogeneity: Tau2:	= 8.69; C	hi² = 2	9.30, d	f= 3 (P		-10 -5 0 5 10			
Test for overall effect: Z = 1.88 (P = 0.06)									Favours [Sarcopenia] Favours [No sarcopenia]

#### B Effect of sarcopenia on quality of life (SF-36 value) in SSc patients

	Sarcopenia No sarcopenia				nia		Mean Difference	Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Corallo 2019	35.74	3.53	26	50.57	4.73	36	62.4%	-14.83 [-16.89, -12.77]	-
Siegert 2018	40.9	18.53	29	48.26	17.61	100	37.6%	-7.36 [-14.94, 0.22]	
Total (95% CI)			55			136	100.0%	-12.02 [-19.11, -4.93]	
Heterogeneity: Tau <sup>2</sup> =				= 1 (P =		-10 -5 0 5 10			
Test for overall effect: Z = 3.32 (P = 0.0009)									Favours [Sarcopenia] Favours [No sarcopenia]

#### C Effect of sarcopenia on pulmonary fuction (FVC predicted value) in SSc patients

	Sarcopenia No sarcopenia				nia		Mean Difference	Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Caimmi 2018	99	26	29	104	23	111	20.0%	-5.00 [-15.39, 5.39]	
Sangaroon 2022	65.85	14.89	41	69.63	15.03	139	80.0%	-3.78 [-8.98, 1.42]	
Total (95% CI)			70			250	100.0%	-4.02 [-8.67, 0.62]	•
Heterogeneity: $Chi^2 = 0.04$ , $df = 1$ (P = 0.84); $I^2 = 0\%$									-20 -10 0 10 20
Test for overall effect: Z = 1.70 (P = 0.09)									Favours [Sarcopenia] Favours [No sarcopenia]

#### D Effect of sarcopenia on CRP in SSc patients



Figure 3 Impact of sarcopenia on clinical characteristics in patients with SSc  $146 \times 136 \text{mm}$  (300 x 300 DPI)

# Sarcopenia in Systemic Sclerosis: Prevalence and Impact - A Systematic Review

### and Meta-analysis

- 1. Table S1 Search strategy by Medline via Ovid SP
- 2. Table S2 Search strategy by Embase via Ovid SP
- 3. Table S3 Search strategy by Web of Science
- Table S4 Search strategy by Cochrane Central Register of Controlled Trials via Ovid SP
- 5. Table S5 The reasons for the exclusion of full-text articles
- 6. Table S6 Characteristics of the included studies
- 7. Table S7 ARHQ Methodology Checklist for Cross-Sectional Study
- 8. Table S8 Newcastle-Ottawa Scale for Cohort study
- 9. Table S9 Meta-regression analyses of sarcopenia prevalence
- 10. Figure S1 Prevalence of sarcopenia by criteria
- 11. Figure S2 Prevalence of sarcopenia by disease subtype
- 12. Figure S3 Prevalence of sarcopenia by mean age
- 13. Figure S4 Sensitivity analysis
- 14. Figure S5 Egger's test for publication bias

# Table S1 Search strategy by Medline via Ovid SP

- 1. exp Scleroderma, Systemic/
- 2. ((Systemic or general\* or diffus\* or progress\* or Limit\*) adj3 sclerosis).mp.
- 3. scleroderm\*.tw.
- 4. SSc.tw.

- 5. 1 or 2 or 3 or 4
- 6. exp muscular atrophy/
- 7. (sarcopen\* or myopen\* or dynapon\* or amyotroph\* or myoatroph\* or myophagis\* or myodegenerat\*).mp.
- 8. ((muscle or muscular) adj5 (atroph\* or wast\* or weak\* or loss\* or mass or degenerat\*)).ti,ab.
- 9. 6 or 7 or 8
- 10. 5 and 9
- 11. exp animals/ not humans.sh.
- 12. 10 not 11

# Table S2 Search strategy by Embase via Ovid SP

- 1. exp systemic sclerosis/
- 2. ((Systemic or general\* or diffus\* or progress\* or Limit\*) adj3 sclerosis).mp.
- 3. scleroderm\*.tw.
- 4. SSc.tw.
- 5. 1 or 2 or 3 or 4
- 6. exp muscle atrophy/
- 7. (sarcopen\* or myopen\* or dynapon\* or amyotroph\* or myoatroph\* or myophagis\* or myodegenerat\*).mp.
- 8. ((muscle or muscular) adj5 (atroph\* or wast\* or weak\* or loss\* or mass or degenerat\*)).ti,ab.
- 9. 6 or 7 or 8
- 10. 5 and 9
- 11. exp animal/
- 12. human/
- 13. 11 not 12
- 14. 10 not 13

Topic= (((Systemic or general\* or diffus\* or progress\* or Limit\*) near/3 sclerosis) or sclerodem or ssc) and (sarcopen\* or myopen\* or dynapon\* or amyotroph\* or myoatroph\* or myophagis\* or myodegenerat\* or ((muscle or muscular) near/5 (atroph\* or wast\* or weak\* or loss\* or mass or degenerat\*)))

# Table S4 Search strategy by Cochrane Central Register of Controlled Trials via

#### Ovid SP

- 1. exp Scleroderma, Systemic/
- 2. ((Systemic or general\* or diffus\* or progress\* or Limit\*) adj3 sclerosis).mp.
  - . scleroderm\*.tw.
- 4. SSc.tw.
- 5. 1 or 2 or 3 or 4
- 6. exp muscular atrophy/
- 7. (sarcopen\* or myopen\* or dynapon\* or amyotroph\* or myoatroph\* or myophagis\* or myodegenerat\*).mp.
- 8. ((muscle or muscular) adj5 (atroph\* or wast\* or weak\* or loss\* or mass or degenerat\*)).ti,ab.
- 9. 6 or 7 or 8
- 10. 5 and 9

Table S5 The reasons for the exclusion of full-text articles

Study	Reason for the exclusion
Norman (2014)	Repeated study
Siegert (2014)	Repeated study
Caimmi (2017)	Repeated study
March (2017)	Repeated study
Doerfler (2017)	Intervention study
Paolino (2018)	Repeated study
Radic (2018)	Not reported sarcopenia prevalence data
	in SSc patients
Remolina (2019)	Repeated study
Sari (2019)	Repeated study
Veronica (2019)	Repeated study
Hax (2020)	Repeated study
Santo (2020)	Repeated study
Sangaroon (2020)	Repeated study
Peterson (2020)	Not reported sarcopenia prevalence data
	in SSc patients
Efremova (2021)	Repeated study
Sorokina (2022)	Not reported sarcopenia prevalence data
	in SSc patients

							BMJ Open			bmjoper			Page 38 of 48
1 2 3 4										bmjopen-2023-078034 by copyright, includi			
	irst author and rear	Country	Study design	Sample size	Mean age(years)	Female,	Disease subtype	Disease duration (years)	SSc diagnostic criteria	aropenia March 2024. I Ing for uses related	Criteria (assessment method detecting sarcopenia)	Prevalence sarcopenia of	of
12 13										Downloa ent Sup to text		Total,n(%)	Diffuse,n( %)
14 15 16 17 18 19 20 21 22	Efremova (2022)	Russia	study Cross-sectional study	47	53.9	47	limited 29 diffuse 18	6	2013 ACR/EULAR	nloaded from http://mmjops hupe和eur (ABES) .20 sxt and data minng, Al trai	LMS (HGS) LMM (DXA) LMS (HGS and Chair rising test) LPP (GS and	10(21.3%)	6(12.8%)
23 24 25 26 27 28	Sangaroon (2022)	Thailand	Cross-sectional study	180	58.8	119	limited 86 diffuse 94	6.2	0,	ng, Al training, and similar t	SPPB) LMM(DXA) LMS(HGS) LPP(GS)	41(22.8%)	30(16.7 %)
29 30 31	A		College of Rheumato							kental Muscl			
32 33	W	orking Group o	on Sarcopenia in Old	People; HG	S, hand grip stre	ngth; 4mGS,	4 m gait speed;	SPPB, Shor	t Physical Perfor	magice Battery	y; GS, gait speed; A	WGS, Asian	
34 35 36 37 38 39 40 41 42	W	orking Group f	or Sarcopenia.							Agence Bibliographique de l			
43 44				Fo	r peer review or	nly - http://br	njopen.bmj.cor	m/site/abou	ıt/guidelines.xht	ml —			

Page 38 of 48

Table S7 ARHQ Methodology Checklist for Cross-Sectional Study

Study	Ite	Ite	Ite	Ite	Ite	Ite	Ite	Ite	Ite	Ite	Ite	Total
	m 1	m 2	m 3	m 4	m 5	m 6	m 7	m 8	m 9	m	m	Score
										10	11	
Caimmi (2018)	Yes	Yes	Yes	Yes	Unc	Yes	No	No	Unc	Yes	No	6
					lear				lear			
Siegert (2018)	Yes	Yes	Unc	Yes	Unc	Yes	No	No	No	Yes	No	5
			lear		lear							
Corallo (2019)	Yes	Yes	Yes	Yes	Unc	Yes	No	No	No	Yes	No	6
					lear							
Rincon (2019)	Yes	Yes	Unc	Unc	Unc	Yes	No	No	No	Yes	No	4
			lear	lear	lear							
Hax (2021)	Yes	Yes	Yes	Yes	Unc	Yes	Yes	No	Yes	Yes	No	8
					lear							
Sari (2021)	Yes	Yes	Yes	Yes	Unc	Yes	No	No	No	Yes	No	6
					lear							
Efremova	Unc	Yes	Unc	Unc	Unc	Yes	No	No	No	Yes	No	3
(2022)	lear		lear	lear	lear							
Sangaroon	Yes	Yes	Yes	Yes	Unc	Yes	No	No	No	Yes	No	6
(2022)					lear							

- Item 1. Define the source of information (survey, record review)
- Item 2. List inclusion and exclusion criteria for exposed and unexposed subjects (cases and controls) or refer to previous publications
- Item 3. Indicate time period used for identifying patients
- Item 4. Indicate whether or not subjects were consecutive if not population-based
- Item 5. Indicate if evaluators of subjective components of study were masked to other aspects of the status of the participants
- Item 6. Describe any assessments undertaken for quality assurance purposes (e.g., test/retest of primary outcome measurements)
- Item 7. Explain any patient exclusions from analysis
- Item 8. Describe how confounding was assessed and/or controlled
- Item 9. If applicable, explain how missing data were handled in the analysis
- Item 10. Summarize patient response rates and completeness of data collection
- Item 11. Clarify what follow-up, if any, was expected and the percentage of patients for which incomplete data or follow-up was obtained


## Table S8 Newcastle-Ottawa Scale for Cohort study

Study	Selection				Comparability	arch2024. Ens@gnen ses @late			Total Score
	Representativeness of the exposed cohort	Selection of the non-exposed cohort	Ascertainment of exposure	Demonstration that outcome of interest was not present at start of study	Comparability of cohorts on the basis of the design or analysis	4. Downloaded from http://lement Superieur (ABES) . ed to text and data mining, As of	Was follow-up long enough for outcomes to occur	Adequacy of follow up of cohorts	
Paolino (2020)	0	1	1	0	1	//bmjoper 3, Al train	0	0	4
					eho,	n.bmj.com/ on June 8, 2025 at Agence Bibliographique de l ing, and similar technologies.			

Table S9 Meta-regression analyses of sarcopenia prevalence


	J	•			
Variables	Coefficient	SE	P value	CI-Lower	CI-Upper
Sample size	-0.0022	0.0026	0.424	-0.0083	0.0039
Average age	0.0210	0.0319	0.532	-0.0545	0.0965
Proportion of	-1.0603	1.3233	0.449	-4.1893	2.0687
female					
Duration of	-0.0606	0.0488	0.255	-0.1760	0.0549
SSc					

Figure S1 Prevalence of sarcopenia by criteria




ES = effect size (prevalence);  $I^2 = I^2$  heterogeneity statistic. A random effects model was used for analysis, and there was no significant difference between subgroups (P = 0.234).

Figure S2 Prevalence of sarcopenia by disease subtype



ES = effect size (prevalence);  $I^2 = I^2$  heterogeneity statistic. The random effects model was used for the analysis, and there was no significant difference between the subgroups (P = 0.339).

Figure S3 Prevalence of sarcopenia by mean age



ES = effect size (prevalence);  $I^2 = I^2$  heterogeneity statistic. The random effects model was used for the analysis, and there was no significant difference between the subgroups (P = 0.539).

Figure S4 Sensitivity analysis





Figure S5 Egger's test for publication bias





## PRISMA 2020 Checklist

ge 47 of 48		BMJ Open BMJ Open	
PRISM	/A 20	by comjopen-2020 Checklist	
Section and Topic	Item #	Checklist item	Location where item is reported
TITLE		ding o	io repertou
Title	1	Identify the report as a systematic review.	Pg. 1, lines 1-2
ABSTRACT		SET CHARGE CONTRACTOR OF THE CO	
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	Pg. 2
INTRODUCTION		att	
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	Pg. 5, lines 1-11
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	Pg. 5, lines 13-15
METHODS		2 6 6	
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	Pg. 6, lines 7-18
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted identify studies. Specify the date when each source was last searched or consulted.	Pg. 5, lines 18-22; Pg. 6, lines 1-5
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used	Table S1-4
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how make review reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	Pg. 7, lines 7-12
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each epoch, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	Pg. 7, lines 12-19
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with act to the study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which study were sought (e.g. for all measures, time points, analyses).	Pg. 6, lines 20-22; Pg. 7 lines 1-3
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, and by sources). Describe any assumptions made about any missing or unclear information.	Table S6 and Figure 3
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how name in previewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	Pg. 7, lines 21-22; Pg. 8 lines 1-6
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	Pg. 8, lines 12-16
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	Figure 2-3
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing sumary statistics, or data conversions.	Pg. 7, lines 17-19
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses timi	Pg. 8, lines



## PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where iten is reported
		en de de la companya	10-12
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was pediormed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	Pg. 8, lines 8-16
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup and pages, meta-regression).	Pg. 8, lines 21-22; Pg. lines 7-8
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	Pg. 9, lines 10-11
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting (arising from from reporting (arising from from from from from from from from	Pg. 9, lines 12-13
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	None
RESULTS		3 2 3	
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to t	Figure 1
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	Figure 1, Table S5
Study characteristics	17	Cite each included study and present its characteristics.	Table S6
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	Table S7-8
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) a effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	Figure 2-3, Figure S1-3
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	Figure 2-3, Figure S1-3
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summare estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	Pg. 11, lines 3-20
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	Figure S1- 3, Table S9
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	Pg. 13, lines 6-7, Figure S4
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	Pg. 13, lines 6-7
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	None
DISCUSSION		de	
Discussion	23a	Provide a general interpretation of the results in the contexportment of the provide a general interpretation of the results in the contexportment of the results in	Pg. 14,

cted by copyrigh



## PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
		Discuss any limitations of the evidence included in the review.	lines 19-22; Pg. 15, lines 1-22; Pg. 16 lines 1-9
	23b	Discuss any limitations of the evidence included in the review.	Pg. 15, lines 6-7
	23c	Discuss any limitations of the review processes used.	Pg. 17, lines 9-20
	23d	Discuss any limitations of the review processes used.  Discuss implications of the results for practice, policy, and future research.  Discuss implications of the results for practice, policy, and future research.	Pg. 16, lines 11-22; Pg. 17 line 1
OTHER INFORMA	TION	3 8 3	
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the value was not registered.	Pg. 5, lines 18-20
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	Pg. 5, lines 18-20
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	None
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	Page 18, lines 11-20
Competing interests	26	Declare any competing interests of review authors.	Page 18, lines 21-22
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	Table S6, Figure 2-3, Figure S1-3
From: Page MJ, McKi	enzie JE,	Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic For more information, visit: <a href="http://www.prisma-statement.org/">http://www.prisma-statement.org/</a> Bibliographique de I	10.1136/bmj.n71
		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	